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Since the successful use of antiretroviral therapy for the prevention of mother-to-child 
transmission of human immunodeficiency virus (HIV), there has been a steady increase in 
the number of infants born to HIV-infected mothers who remain uninfected. The 
characteristics of these HIV-exposed uninfected infants are not well known, including growth 
and other health outcomes.  
The International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) 
research strategy 2011-2016 includes specific studies in pregnant women, infants, children 
and adolescents. This study addresses one of the IeDEA-SA objectives, namely to establish 
and describe a sub-cohort of HIV-infected pregnant women and their exposed infants. Part 
A, the protocol, includes background information on sites contributing to this cohort of HIV-
exposed uninfected (HEU) infants. It also details the aims, objectives and methodology of 
this study.  
Part B, the literature review, discusses what is known about HIV-exposed uninfected infants 
to date. It includes maternal disease factors, the use of antiretroviral therapy and the 
association between feeding modality and growth, focussing on studies conducted on the 
African continent.  
Part C, the manuscript, details the methodology, results and their interpretation of 
longitudinal analysis of growth among HEU infants in the IeDEA-SA collaboration. This 
cohort of HEU infants included 2621 infants from two South African sites. The median birth 
WAZ was -0.65 (IQR -1.46; 0.0), 51% were male and there was a median of 2 visits per 
infant. The feeding modalities practised were as follows: 0.5% exclusive breastfeeding, 7.9% 
unknown breastfeeding exclusivity, 78.6% mixed breastfeeding and 10.6% formula feeding. 
Mothers with a CD4 <200 cells/µl delivered infants with a lower birth WAZ (adjusted ß -0.253 




mothers who did not receive antiretroviral (ARVs) drugs delivered infants with a lower birth 
WAZ (adjusted ß -0.49 [95% CI -0.78; -0.20], p = 0.001) compared to mothers who received 
antenatal ARVs. Antenatal maternal ARVs and CD4 cell count did not have an effect on 
postnatal growth. Mixed effects models using maximum likelihood estimation for the 
longitudinal analysis of growth showed that exposure to breast milk positively influenced 
growth, albeit the effect was small. Infants with a birth weight <2 500g (ß 0.069 [95% CI 
0.061; 0.078], p <0.0001) experienced faster growth within the first 28 weeks of life 
compared to infants with a birth weight ≥2 500g. In this cohort of South African HEU infants, 
less severe maternal disease and the use of ARVs positively impacted birth weight. Mixed 
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Acronyms and abbreviations 
ART Antiretroviral therapy 
ARVs Antiretroviral drugs 
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EBF Exclusive breastfeeding 
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HIV Human Immunodeficiency Virus 
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IQR Inter-quartile range 
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MF Mixed feeding 
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NVP Nevirapine 
PaBF Partial breastfeeding 
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HIV-exposed uninfected (HEU) infants are a growing population in southern Africa. The 2010 
South African antenatal survey reports a 30.2% prevalence of HIV infection among pregnant 
women. Most of the infants born will be exposed but not infected. These infants are an 
overlooked group vulnerable to morbidity and mortality. We aim to describe the 
characteristics of HEU infants within the IeDEA-SA network and examine feeding practices 




HIV-exposed uninfected children (HEU) are a growing population in southern Africa. Nearly 
40% of infants are born to HIV-infected mothers and the majority of these are likely to be 
uninfected [1]. Specifically, in South Africa in 2010, the prevalence of HIV infection among 
pregnant women was 30.2% [2]. These exposed uninfected children are an overlooked 
group of children at high risk of both morbidity and mortality [3].  
 
Much research has been conducted examining HIV-infected women in Africa but most of this 
research has been focused on the prevention of mother-to-child transmission (PMTCT) via 





Long-term consequences of in utero ARVs 
 
Knowledge of the long-term impact of in utero exposure to antiretrovirals (ARVs) on growth 
and development is limited and most studies that have examined outcomes of in utero ARV 
exposure have had relatively brief follow-up periods [5]. HIV-exposed  African infants are not 
only exposed to in utero ARVs but also through breastfeeding as ARVs are present in breast 
milk if mothers are on antiretroviral therapy [4]. Such exposure is likely to become more 
frequent as countries increasingly move to adopt option B/B+ in terms of the World Health 
Organization (WHO) guidelines [6]. The distinction between developed and developing 
countries is evident as in developed countries most HIV-exposed infants are formula fed. In 
contrast, in developing countries, formula feeding is only recommended by the WHO if it is 
affordable, feasible, acceptable, safe and sustainable (AFASS criteria) [4, 7]. South Africa 
recently changed its HIV-exposed infant feeding policy to support breastfeeding with the use 
of ARVs to prevent transmission rather than formula feeding by HIV infected mothers [8]. 
The policy states that  if mothers are on lifelong ART, infants are to receive nevirapine (NVP) 
for 6 weeks but if mothers are not on lifelong ART, infants are to receive NVP for prophylaxis 
until the cessation of breastfeeding [8]. 
 
Infant feeding and HIV 
 
The safest feeding option for all infants, for those who are unexposed to and those who are 
exposed to HIV (particularly in resource-limited settings), is exclusive breastfeeding [9] but 
there have been conflicting infant feeding messages for HIV infected mothers [4, 10]. A 
study in Malawi [11] examined the effects of the cessation of breastfeeding among HEU 
infants and found that not breastfeeding was significantly associated with higher mortality 




dilemma between protecting exposed uninfected infants from the negative consequences of 
not breastfeeding and keeping these infants HIV free as the virus is known to be transmitted 
via breast milk [11].  
 
Infant growth and ARVs 
 
The effect of ARV exposure on postnatal growth has been examined in numerous studies. 
Two cohorts in Botswana showed that HEU infants exposed to highly active antiretroviral 
therapy (HAART) had lower anthropometric markers when compared to those exposed to 
single dose, short course zidovudine. The HAART exposed infants had lower birth weights 
but weight had caught up by 3 months of age, while lower average length persisted for the 
first 6 months of life [12]. 
 
Other African studies have also examined growth among HEU infants, with many studies 
conducted prior to the introduction of prophylactic antiretroviral therapy.  
 
A prospective cohort study conducted in The Democratic Republic of Congo (1989-1992) 
among infected and uninfected mothers [13] examined growth amongst infants by maternal 
and infant HIV status. Similar to the two Botswana studies, HEU infants had lower birth 
weights compared to unexposed infants and by 3 months of age, HEU infants had similar 
anthropometric profiles compared to unexposed infants. This trend continued until aged 20 
months when follow up ceased. A prospective Rwandan study over the same time period 
(1988-1993) found that both the mean z-score for weight-for-age and height-for-age amongt 
HEU infants were statistically significantly lower when compared to unexposed infants at 6 
months of age. Height-for-age and weight-for-age were then comparable from 9 months of 




Babies Project) study conducted in Zimbabwe (1997-2000) also found that HEU infants had 
significantly lower birth weights when compared to unexposed infants [15].  
 
A Zambian study investigating early growth (until 16 weeks of age) of infected and 
uninfected infants (2001-2003) found that infants of infected mothers had lower weight-for-
age and length-for-age z-scores at 6 and 16 weeks when compared to uninfected mothers. 
This difference was only statistically significant for weight at 6 weeks of age. A major 
limitation of this particular study is that infant HIV status was unknown. The study authors 
had attempted to overcome this shortfall by limiting the analysis to infants who were still alive 
and assumed HIV-free between the ages of 2 – 4 years [16]. 
 
These African studies contrast the European Collaborative Study (1987-2001) where 
children were followed-up to the age of 10 years. This study found no major differences in 
growth between HEU children and children in the 1990 British growth standards [17].  
 
Infant feeding options and growth 
 
In a study examining growth faltering following breastfeeding cessation among HEU infants, 
it was found that an absence of breastfeeding was associated with significant decreases in 
weight-for-age z-scores after adjusting for possible confounders [18]. In this study among 
Zambian women, nearly 40% of HEU infants experienced moderate-to-severe malnutrition 
by the age of 2 years. Arpadi et al also found declines in length compared to WHO growth 
standards [18]. In a review on patterns of postnatal growth in both HIV-infected and 
uninfected exposed children, the authors concluded that the difference in early growth of 
HEU compared to healthy controls was small but also that data on growth beyond 2 years of 
age was limited and that follow-up periods may not be of adequate length to fully capture 





A Kenyan study looking at the outcomes of HEU infants and the efficacy of PMTCT in a 
resource-constrained setting found that in children with documented feeding modality, there 
was no difference in the  combined endpoint of HIV infection or death by feeding mode [20]. 
Moreover, formula feeding did not confer a benefit at 18 months of age (when compared to 
breastfeeding). Among HIV-infected mothers who received prophylactic ART, there was a 
significant reduction in HIV infection and death of their infants  at both 3 and 18 months of 
age [20]. 
 
It is therefore clear that although breastfeeding does confer a risk of transmission of HIV, the 
use of ARVs in both mothers and their infants can help stem this. Furthermore, there are 
other benefits of breastfeeding that formula feeding cannot confer, especially when one 
considers protection against infectious diseases including acute respiratory tract infections 
and diarrhoea [21]. 
 
Despite the short-term nature of studies examining the effects of extended exposure to 
antiretroviral drugs, HEU infants can evidently benefit from prophylactic use. Knowledge of 
the characteristics of these infants has the ability to provide guidance to the type of 
healthcare they will require in the long term. It will also assist in providing improved care to 
HIV-infected mothers to ensure their infants are born, and remain, uninfected in spite of their 




As mentioned previously, HEU infants are frequently overlooked and this study will provide 




This study will describe a cohort of HIV-exposed uninfected infants within the International 
Epidemiological Databases to Evaluate AIDS Southern Africa (IeDEA-SA) network.  







1. To describe the cohort of HEU infants within the IeDEA-SA network. This will include 
gender, weight and height classification according to the WHO z-scores, 
anthropometric measures at birth and follow-up visits, gestational age, feeding 
modality, opportunistic infections and social variables such as the primary care giver. 
The antenatal and postnatal exposure of ARVs of both the mother and the infant will 
also be described. 
2. To examine growth outcomes among HEU infants during the first 2 years of life 
3. To compare effects of different ARV exposures of HEU on infant growth 
III. Methodology 
 
1. Study design 
 
This will be a retrospective cohort analysis of data from HIV-exposed uninfected infants 






All collaborating IeDEA-SA sites will be invited to contribute data to the analysis (two South 
African sites and one in and Mozambique). 
 
The IeDEA-SA cohort profile has been described elsewhere [22, 23].  
 
Table 1 contains a brief description of the sites that will be contributing to this study.  
 
Table 1 Summary of contributing IeDEA-SA sites 
Site Setting No. of HEU 
infants 
Follow-up period 
Rahima  Moosa Mother 
and Child Hospital 
Johannesburg, South 
Africa; urban 6000 2500 with at least 1 visit 
Centro de Investigaçao 
em Saude de Manhiça 
(CISM) 
Manhica, 
Mozambique; rural 496 12 months 
McCord Hospital Durban, South Africa; urban 802 18 months 
 
The sites all collect baseline variables including date of birth, birth anthropometry and 
intended feeding method. PMTCT information is collected for both mother and infant. 
Feeding and anthropometry are assessed per visit. McCord Hospital and Rahima Moosa 
Mother and Child Hospital collect additional information including source of income and 





2. Research procedures and data collection methods 
 
Permission will be obtained from collaborating IeDEA-SA sites to utilise data on HEU infants 
in the analysis. The data, although held at the University of Cape Town, belongs to the 
individual sites and thus permission will be needed before analysis can commence. All sites 
have existing ethical approval from their respective institutional Research Ethics Committees 
to contribute data to IeDEA-SA Collaborative analyses. 
 
Sample size will not be calculated but all infants from participating sites who are exposed but 
uninfected will be included in the analysis. 
 
The data that will be used for analysis are anonymised prior to importing into the IeDEA 
database and any identifying information is held at the individual sites. 
 
Inclusion and exclusion criteria 
 
Although the aim is to include all HEU infants from participating sites, this may not be 
possible due to missing variables. 
The exclusion criteria will thus exclude infants who have an unknown HIV status at first visit.  
This study will be limited to those where the pregnancy history, including ARV exposure, is 







The individual contributing sites within the IeDEA-SA network collect routine data. This data 
is stored within electronic databases or as paper records. A data transfer protocol (DTF) has 
been developed to import data from each site to the database based at the University of 
Cape Town. The DTF was updated to include the capturing of information on HEU infants 
(Addendum A).  The following tables in Addendum A are of particular importance for HEU 
infants: tables 1.1, 1.3, 2, 3, 5.1, 5.2, 6, 7, 8 and 9. 
2. Variables 
 
Table 2 lists some of the variables included in the data transfer protocol. 
 
Table 2 Summary of list of variables 
Variable Name Type of Variable 
Date of birth Numerical 
Gender Binary 
Weight, height, head circumference, mid-upper arm circumference Numerical 
Gestational age Numerical 
Feeding modality Nominal 
Opportunistic infections Nominal 
Social variables e.g. caregiver Nominal 
ARV exposure (mother and infant) Nominal 
 
The exhaustive list of individual variables can be found within the data transfer protocol in 
addendum A. 
 
The outcomes will be the WHO weight-for-age, height-for-age and weight-for-height z-scores 




3. Validity and reliability of measuring instruments 
 
The DTF protocol is based on the HICDEP (HIV Cohorts Data Exchange Protocol, see 
http://www.hicdep.org/) and has been utilised for transfer of data of infected adults and 
children. Additional variables have been included for HEU infants. 
V. Data analysis plan 
 
1. Data analysis 
 
The data analysis will be of pooled retrospective data from the IeDEA-SA cohorts using the 
agreed format for HEU infants. The statistical package- Stata v12.0 will be used to perform 
the analysis. 
 
Characteristics of HEU infants that will be described include weight and height z-scores, 
ARV exposure history and feeding modalities. Continuous variables will be summarised 
using means/medians and categorical variables with proportions. 
 










Giving the infant breast milk only (including expressed breast milk), and drops or 




The predominant source of nutrition for the infant is breast milk. However, the 
infant may also receive water or water-based drinks; fruit juice; oral rehydration 
salts; drop and syrup form vitamins, minerals and medicines; and folk liquids 
(liquids used for non-nutritional purposes e.g. tea for relief of colic). With the 




Giving a baby some breastfeeds, some artificial feeds, either milk or cereal or 
other food 
Mixed feeding (MF) 
 
Giving a baby both breast milk and other foods or liquids, including water (i.e. 
includes predominant and partial breastfeeding) 
Exclusive formula 
feeding (EFF) 
Giving the infant only commercial infant formula for the first six months of life 
 
 
Linear and/or logistic regression models will be utilised to determine differences in growth 
outcomes among HEU infants by the different types of ARV antenatal exposure and 








Table 4 Dummy table - HEU infant characteristics 
Characteristics Overall By sex Per study site 
  M F A B C 
% male  - -    
% female  - -    
Median (IQR) gestational 
age 
      
Median (IQR) birth weight       
Median (IQR) birth length       
Median (IQR) birth head 
circumference 
      
Median(IQR) WHO 
weight-for-age z-score 
      
Median(IQR) WHO 
length-for-age z-score 
      
Median (IQR) WHO 
weight-for-length z-score 
      
% breastfed(all definitions 
– 3mths) 
      
% breastfed (all 
definitions – 6mths) 
      
Feeding at 3 months:  
% EBF        
% PrBF       
% PaBF       
% MF        
% EFF        
Feeding at 6 months:  
% EBF        
% PrBF       
% PaBF       
% MF        
% EFF        
% Solids + BF at 1 yr       
% Solids + BF at 18mths       
% Solids + FF at 1yr       
%Solids + FF at 18mths       
Prophylaxis:  
Mother   
Regimens by infant 
feeding mode (%) 
      
Infants – regimens %       
Regimens by infant 
feeding mode (%) 






Table 5 Dummy table - Maternal characteristics 
Characteristics Overall Per study site 
  A B C 
Mean age     
Mean parity     
% intend to BF     
















    
Median VL after 
pregnancy 




    
% regimens     
Prophylaxis  
% not on ART 
pre-pregnancy 




    




    




    
% regimens     
% first ARVs 
during labour 
    
% regimens     
% ARVs given 
post delivery 
    
% regimens     
% ARVs 
postnatal 
    






Table 6 Dummy table – HEU infant outcomes 
Outcomes Overall By sex Per study site 
  M F A B C 
1 year of age  
Median (IQR) WHO 
weight-for-age z-score  
      
Median (IQR) WHO 
length-for-age z-score  
      
Median (IQR) WHO 
weight-for-length z-score  
      
2 years of age  
Median (IQR) WHO 
weight-for-age z-score  
      
Median (IQR) WHO 
length-for-age z-score 
      
Median (IQR) weight-for-
length z-score 
      
VI. Ethics 
 
1. Study protocol approval 
The International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) 
Collaboration (formerly known as the Observational Antiretroviral Studies in Southern Africa 
[OASIS] Collaboration) has approval from the University of Cape Town Research Ethics 
Committee to collate anonymised routine individual patient data from HIV care and treatment 
programmes, including that of HIV exposed uninfected infants (HREC REF 084/2006). Each 
participating cohort has approval from their institutional human research ethics committee to 
participate in the collaboration and contribute data.  
These details can be found in Appendices B and C. 
2. Site participation 
The contributing IeDEA-SA cohorts will provide permission to utilise their data. All sites have 




The individual sites will have received informed consent from patients if this was required by 
the respective institutional research ethics committee. Most of the research ethics 
committees felt that informed consent was not required as only routine patient data that was 
already being collected for monitoring and evaluation purposes was included, and all data is 
transferred to the IeDEA-SA Data Centre only after it has been anonymised. 
3. Privacy and confidentiality 
The data imported into the IeDEA database from each site is anonymised and identifying 
information is held at the individual sites. Thus, the privacy and confidentiality of all 
participating individuals is ensured. 
4. Reimbursement for participation 
Sites are funded and remunerated according to their contributions to the IeDEA network.  
5. Risks and benefits of participation 
Potential benefits 
The contributing sites will be provided with the study results. As the data is anonymised 
there is no direct benefit to individual patients from the contributing sites. However, the sites 
will have the characteristics on the sub-cohort of infants who are exposed to HIV but 
uninfected.  
The description of these infants may allow study sites to better tailor healthcare for these 
infants if it is within their scope of practice. Alternatively, appropriate referrals to other 
healthcare providers can be made.  
Potential risks 
There are minimal risks to those sites participating in the study. Anonymity of patients is 




password protected and these passwords are made available telephonically or via facsimile 
only. The purpose of this study is to expand the current knowledge base of HEU infants.  
 
6. Reporting to stakeholders 
As the data is part of the IeDEA-SA cohort collaboration, the results of this study will be 
disseminated to all participating IeDEA-SA sites. It will be presented at appropriate academic 




Table 7 Gantt Chart - timeline of actions 
Timeline
Actions Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug
Finalise concept sheet
Circulate concept sheet within IeDEA
Finalise protcol
Finalise data transfer protocol
Departmental approval submission
Finalise contributing sites




Submit to HREC (2014 updated requirements)
Write-up analysis
Final report





The sites contributing to the collaboration are funded by IeDEA. No additional resources are 
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In the final analysis the Mozambican data were not included as there were substantial delays 
on the part of the contributing cohort in providing data and queries that could not be 
resolved.  
Opportunistic infections and introduction of solids 
In the data provided by McCord and Rahima Moosa Mother and Child hospitals, the 
introduction of solids and opportunistic infections were not assessed as this data was not 
routinely collected.  
Birth weight 
Factors affecting birth weight were investigated separately from growth as birth weight was 
found to be an important determinant of postnatal growth. 
Data analysis 
Mixed effects models were used to assess growth among the HIV exposed uninfected 
infants. The mixed effect model was selected as it allows for fixed and random effects when 
looking at subjects with repeated measurements. The analysis of cohort data does not 
assess causality. In addition, as this analysis was based on routine data, missing data was 
taken into account by restricting to those with complete information or including a missing 












Globally, and particularly in sub-Saharan Africa, HIV-exposed uninfected (HEU) infants are a 
growing population. This sub-population will continue to increase in number as access to 
antiretroviral drugs (ARVs) continues to improve, especially within the South African 
prevention-of-mother-to-child transmission (PMTCT) programme that is no longer vertical but 
aimed to be integrated into all maternal and child health services [1]. In 2010, The World 
Health Organization (WHO) introduced Option B, combination antiretroviral therapy (ART) 
for the duration of pregnancy and breastfeeding with lifelong ART for women with a CD4 
count of <350 cells/µl [2] . Malawi modified this to Option B+, lifelong ART for all pregnant 
and breastfeeding women, irrespective of CD4 cell count. Countries are increasingly 
adopting Option B+ for their PMTCT programmes [3]. Consequently, more infants will be 
exposed to triple therapy in utero and during breastfeeding, thus a further increase in the 
numbers of infants who are exposed yet uninfected is likely to occur.  
In South Africa, the prevalence of HIV among pregnant women in 2011 was 29.5% [4] and 
remained steady in 2012 [5]. Across the public and private healthcare sector approximately 
87% of all HIV-infected pregnant women in South Africa received ARVs for the purposes of 
PMTCT in 2011 [6]. An evaluation of the effectiveness of the PMTCT programme was 
conducted in 2010 by the Medical Research Council (MRC) of South Africa. This cross-
sectional, facility-based survey examined, inter alia, early HIV transmission rates (4-8 weeks 
postpartum) among exposed infants. Overall, the early transmission rate of HIV was 3.5% 
(variable across the nine provinces) and infection prevalence was 1.5%, thus, by 8 weeks of 
age, the majority of infants are exposed yet uninfected [7]. 
The focus of this literature review will be on these HEU infants, with particular focus on the 






The aim of this literature review is to appraise published studies, including observational 
studies, randomised controlled trials, and meta-analyses where HEU infants were included 
as subjects. It is only with the success of PMTCT programmes that the sole focus was 
diverted from HIV-infected infants, and included HEU infants. Thus, studies solely 
investigating HEU infants, particularly historically, are relatively uncommon. 
The objectives of this review are to investigate the following, focussing on Africa: 
 The effect of HIV exposure, maternal HIV clinical stage and the maternal and infant 
exposure to antiretroviral drugs in conjunction with the effect of feeding modality on 
the postnatal growth of uninfected infants. 
 The differences in postnatal growth outcomes based on infant feeding modality.  
HIV exposure in utero and perinatally has multiple possible effects on exposed infants 
including the risk of acquiring HIV and an increased risk for other infection [8]. As this review 
has a particular focus on growth and feeding, other outcomes in HEU infants such as HIV 
transmission, infectious disease morbidity and mortality will not be discussed but they are 
acknowledged. Infant feeding, particularly breastfeeding, not only impacts nutritional status 
and growth, but infectious diseases and mortality too [9]. Owing to this interaction, and the 
known transmission of HIV via breastfeeding [10], studies examining morbidity (including 
HIV transmission) and mortality were also reviewed. An understanding of factors increasing 
the risk of HIV transmission is important to minimise infection and increase the number of 
infants who remain uninfected, despite HIV exposure.  
There are key contextual differences between developed and developing countries, including 
access to, and guidelines on the use of, antiretroviral drugs (ARVs) and infant milk formulae. 




outcomes) between developed and developing countries, especially when looking at infant 
feeding modes [11, 12]. 
 
1.2 Search strategy 
 
PubMed (US National Library of Medicine, National Institutes of Health) was used to search 
the Medline database. A combination of Medical Subject Headings (MeSH terms) and key 
words were used when searching PubMed. The search terms are as follows: 
 ((feeding[All Fields] AND ("hiv"[MeSH Terms] OR "hiv"[All Fields]))  
 (("breastfeeding"[MeSH Terms] OR ("breast"[All Fields] AND "feeding"[All Fields]) OR 
"breastfeeding"[All Fields] OR "breastfeeding"[All Fields]) AND ("hiv"[MeSH Terms] 
OR "hiv"[All Fields]))  
 (feeding[All Fields] AND ("hiv"[MeSH Terms] OR "hiv"[All Fields]) AND exposed[All 
Fields] AND uninfected[All Fields])  
 (("hiv"[MeSH Terms] OR "hiv"[All Fields]) AND exposed[All Fields] AND 
uninfected[All Fields] AND ("infant"[MeSH Terms] OR "infant"[All Fields] OR 
"infants"[All Fields]))  
 (("hiv"[MeSH Terms] OR "hiv"[All Fields]) AND exposed[All Fields] AND 
uninfected[All Fields] AND ("infant"[MeSH Terms] OR "infant"[All Fields] OR 
"infants"[All Fields]) AND ("growth and development"[Subheading] OR ("growth"[All 
Fields] AND "development"[All Fields]) OR "growth and development"[All Fields] OR 
"growth"[All Fields] OR "growth"[MeSH Terms]))  
 (("hiv"[MeSH Terms] OR "hiv"[All Fields]) AND exposed[All Fields] AND 
uninfected[All Fields] AND ("infant"[MeSH Terms] OR "infant"[All Fields] OR 




Fields] AND "development"[All Fields]) OR "growth and development"[All Fields] OR 
"growth"[All Fields] OR "growth"[MeSH Terms]))  
 ("hiv"[MeSH Terms] OR "hiv"[All Fields]) AND exposed[All Fields] AND uninfected[All 
Fields])  
There was some overlap in the articles found based on the above search strategy but it 
yielded articles looking at HIV and feeding modality, and the growth and development of  
HEU infants. I set up monthly updates from PubMed using the same search terms, and set 
up a Google Scholar alert for new articles on HEU infants.  
The alerts were set up as follows: 
 [ intitle:"hiv exposed uninfected infants" ] 
 [ intitle:"hiv exposed uninfected" infants growth ] 
In addition to this strategy, I used the reference list of numerous articles found as a further 
source for articles on HEU infants, particularly since HEU infants have only recently been 
studied as primary subjects. Earlier studies looking at HIV infection and PMTCT among 
infants mention HEU infants, but they were often not the focal point of the study. The search 
for articles for this review was conducted periodically between June 2012 and September 
2013. Thereafter, the monthly updates and alerts were reviewed and articles included as 
appropriate. For the purposes of this review, articles found through to December 2013 were 
assessed. 
Studies were included if HEU infants were part of the analyses. In addition, selected studies 
needed to have examined growth and/or included information on feeding method as well as 
have conducted an analysis of the effect of feeding on growth (and/or mortality and 
morbidity) and not merely provided descriptive statistics. Studies from African countries were 
included. Studies were excluded if HIV-infected infants were the only subjects. Furthermore, 




However, efficacy trials with a feeding component were included, as breastfeeding is known 
to increase the risk of transmission and it is important to consider the extent to which use of 
ARVs mitigates this risk [10].  
2. Characteristics of studies  
 
Twenty-four publications met the inclusion criteria, with three studies resulting in more than 
one publication from the same primary study, but with a different outcome. Fifteen 
publications were on results from randomised controlled trials, six on results from 
observational studies, and three were meta-analyses. 
The characteristics of studies included in this literature review are described in tables 1 
through 4. Tables 1 and 2 cover randomised controlled trials, while tables 3 and 4 
summarise observational studies and meta-analyses, respectively. These characteristics 
reflect study quality and comparability. The study characteristics are intended to provide a 
brief background to each study and the context in which they occurred. Minor differences in 
studies influence their comparability. For instance, the criteria for the use of ART,  for 
pregnant women was initially a CD4 cell count of ≤200 cells/µl, increasing to ≤ 350cells/µl [2] 
and with the latest WHO consolidated guidelines stating that all pregnant HIV-infected 
women should receive ART [13]. Similarly, the availability and use of ARVs changed over 
time for both mothers and infants. Changing one factor, e.g. infant prophylaxis for varying 
durations or doses, will reduce comparability of studies. 
Tables 5 to 7 contain additional details reflecting the quality of the studies including sample 
size, ARV use and feeding method together with how feeding modality was defined. These 
quality measures will impact the interpretation of the study results. Sample sizes influence 
the magnitude of effects as well as the size of confidence intervals. This is particularly 




Table 1 Study details: randomised controlled trials 
Authors Country Additional study details 
Thior et al 2006 [14] Botswana, Mashi Study RCT with 2X2 design, comparing interventions to prevent perinatal transmission (part 1) and 
reduce postnatal HIV infection and mortality (part 2).  
Part 1 investigated the efficacy of adding sdNVP to maternal and infant ZDV to reduce perinatal 
MTCT. 
Part 2 was randomised, unblinded and looked at the efficacy of ARVs per feeding modality. 
Mothers were randomised into: 
i) BF plus infant ZDV for 6 months 
ii) FF plus infant ZDV for 1 month 
 
Kuhn et al 2005 [15] 
Kuhn et al 2007 [16] 
Kuhn et al 2009 [17] 
Arpadi et al 2009 [18] 
Kuhn et al 2010 [19] 
Zambia Exclusive Breastfeeding 
study (ZEBS) 
RCT investigating early cessation of breastfeeding. All women were counselled to breastfeed 
exclusively through to 4 months of age. Women were then randomised into: 
i) Abrupt cessation BF at 4 months (intervention) 
ii) Continued EBF, with gradual weaning until 6 months (control) 
Analysis restricted to HEU infants still BF by 4months. Arpadi et al (2009) evaluated the effect 
of timing of BF cessation on growth among HEU. 
 
Coutsoudis et al 2001 [20] South Africa, Vitamin A Study RCT investigating vitamin A to reduce MTCT of HIV. Pregnant women were randomised into: 
i) Vitamin A 
ii) Placebo 
Mothers were counselled on transmission risk with BF as well as the health benefits of BF, 
infant feeding was based on mother‘s informed choice. 
 
Nduati et al 2000 [21] 
Mbori-Ngacha et al 2001 [22] 
McGrath et al 2012 [23] 
Kenya, Breastfeeding and 
transmission of HIV study 
Pregnant women were randomised into: 
i) Breastfeeding 
ii) Formula feeding 
 
Illiff et al 2005 [24] Zimbabwe Vitamin A for Mothers and 
Babies Project (ZVITAMBO) 
Aim: measure effect of single dose postpartum vitamin A supplementation on maternal and 
neonatal health outcomes (4 vitamin A groups, within 96 hours of delivery) 
Secondary objective: investigate breastfeeding associated infant feeding practices and the role 
in HIV  transmission 
Muhangi et al 2013 [25] Uganda Trial of anthelminthics in pregnancy, 2x2 factorial design 
i) Albendazole vs. placebo 
ii) Praziquantel vs. placebo 
Retrospective analysis was conducted looking at differences in growth at 12months of age 









Authors Country Additional study details 
Taha et al 2011 [26, 27] Malawi, PEPI-Malawi A randomised, controlled, open-label phase 3 clinical trial. Infants were randomised into 3 
arms:  
i) Control: oral sdNVP at birth and twice daily for 1 week 
ii) Control regimen + extended daily NVP until age 14 weeks 
iii) Control regimen + extended daily NVP and ZDV until age 14 weeks 
 
Homsy et al 2010 [28] Uganda RCT evaluating clinical and laboratory based strategies for monitoring ARV therapy with an 
MTCT sub-study. 
 
Natchu et al 2012 [29] Tanzania, Trial of Vitamins Aim: Examine the effects of oral supplementation of multivitamins on disease progression in 
mothers, MTCT and mortality and morbidity outcomes  in mothers and infants 




Table 2 Characteristics of randomised controlled trials 
Authors Study details 
 Country & time Inclusion criteria Exclusion criteria 
  Mother Infant  
Thior et al 2006 [14] Botswana 
2001-2003 
Mashi study 
≥18years of age 
33-35 weeks gestation 
HIV-infected 
Hb ≥80g/L; absolute neutrophil count ≥1000 cells/mm;  no 
intolerance to ZDV & NVP 
 
  




Analysis restricted to 661 mother-infants pairs where infants 
remained uninfected and were still BF at 4 months. 
 
  
Kuhn et al 2007 [16] 
 
Kuhn ‘07: 
Nested observational cohort study within RCT comparing 




743 infants HIV-free to 6 
weeks and still BF at 4 
months 
 
Kuhn et al 2010 [19] 
 
Kuhn ‘10: 
749 uninfected infants at last PCR – looking at effect of 
weaning at different ages on mortality 
 
Kuhn ‘10: 




Kuhn et al 2005 [15] Kuhn ‘05 
Restricted to mothers who gave birth to live-born infants  
before December 2003 
  
Arpadi et al 2009 [18]  Arpadi‘09: 
595 HEU live singleton 
births 
Arpadi ‘09: 
In this analysis, if 
breastfed <120 days 
were excluded & infants 
LTFU/died before 150 
days were excluded to 
minimise attrition during 
the weaning period for 
the intervention group 
Coutsoudis et al 2001 
[20] 
Durban, South Africa 
1995-1998 
South African Vitamin A 
study 
HIV-infected mothers were recruited from antenatal clinics for 
Vitamin A trial and chose feeding method based on informed 
choice. Dependent on choice, mothers were counselled 
appropriately and feeding choice supported. Formula had to be 






Authors Study details 
 Country & time Inclusion criteria Exclusion criteria 
  Mother Infant  
Nduati et al 2000 [21] 
 
Nairobi, Kenya.  
1992-1998 
Breastfeeding and 
Transmission of HIV 
study 
HIV-infected mothers residing in Nairobi, with access to 
municipal treated water. Mothers had to agree to mode of 
feeding as randomised prior to enrolment. At 32 weeks 
gestation women were randomised into either BF or FF arms. 
Formula was provided free of charge. 
 
Live-born singleton  & 
first-born twins included 
in analysis 
 
Mbori-Ngacha et al 
2001 [22] 
 
Mbori-Ngacha‘01: focus on morbidity and mortality between BF 
& FF infants. 
 
  
McGrath et al 2012 
[23] 
McGrath‘12: prevalence of stunting – looked at ITT & PP 
analysis. 
 
 McGrath ‘12: 
Infants testing HIV 
positive at birth and 
infants with no follow-up 
information after birth 






Mother-infant pairs were eligible if neither had a life-
threatening condition and planned to stay in Harare after 
delivery.  Mothers had to be HIV-infected at delivery. 
Birth weight ≥ 1500g, 
singleton 
 
Infants had to be PCR 
negative at 6 weeks and 
have feeding information 
available at birth, 6 








Pregnant women eligible if they were well, resident in Entebbe, 
planned to deliver at the hospital, willing to participate and 
know HIV status 
 Pregnant women 
excluded if Hb<8g/dl, 
clinically apparent liver 
disease, bloody 
diarrhoea, abnormal 
pregnancy, history of 











Authors Study details 
 Country & time Inclusion criteria Exclusion criteria 
  Mother Infant  
Taha et al 2011 [26] Malawi 
2004-2009 
PEPI-Malawi 
HIV-infected pregnant women (or had delivered within the 
previous 24 hours), ≥18 years of age (if <18 years, guardian 
permission) receiving antenatal care or who delivered at one of 
the 5 study healthcare facilities. Mothers had to be resident in 
the area, willing to return for postnatal follow-up up to 2 years 
and intend to BF [27]. 
 
In this analysis included if 
BF at 14 weeks and HEU 
at 6 months of age 
Infants with life-
threatening conditions 
Homsy et al 2010 [28] Uganda 
2003-2007  
All HIV-infected female index clients who delivered one or 
more live infants were enrolled. 
 
  
Natchu et al 2012 [29] Tanzania 
1995-1997 
Trial of Vitamins 
HIV-infected pregnant women between 12 and 27 weeks 
gestation 
Infants included in 
analysis if uninfected at 
birth 
Infants were excluded if 
HIV-infected at birth/first 
visit, no follow up visit 
before 2yrs of age, 
unable to determine EBF 
duration, died within 1 
month of stopping EBF 
and if HIV status was 
unknown. 




Table 3 Characteristics of observational studies 
Authors Study details 
 Country & time Inclusion criteria Exclusion criteria 
  Mother Infant  
Landes et al 2012[30] Retrospective cohort , 
Malawi 2008-2009 
HIV infected mothers who attended facilities in the region with 
due date between 1 March – 31 May 2008 
For every HIV-infected mother identified in the register, the 
next uninfected mother was selected as a control 
 
  
Bobat et al 1997[31] Prospective cohort, 
South Africa 
1990-1993 













HIV infected & uninfected mothers attending antenatal clinics 
in KZN, >16 years of age, planned to stay in study area for at 
least 3 months after delivery & gave written consent.  Feeding 
choice was supported by counsellors doing home visits 
(whether antenatal choice or present choice). This analysis 
was restricted to HIV infected mothers. 
 
  
Patel et al 2010 [33] Patel‘10: 
For this analysis, maternal HIV had to be known 
Patel‘10: 
Children had to 
have a 
gestational age 
between 18 and 






For the reference infant 
population (born to uninfected 
mothers), infants were excluded 
if weighed <2500g and were 
preterm and observations ± 4SD 
of sample median were 
excluded 
Makasa et al 2007 [34] Longitudinal cohort 
study, Zambia 
2001-2003 
Pregnant women (32-34weeks gestation) who resided in 
Chilenje clinic catchment, known HIV status, intention to BF & 
signed informed consent 
 
  
Goga et al 2012 [35] Prospective 
observational cohort , 
South Africa 
2002-2003 
Consecutive HIV positive & negative women were enrolled 3:1 
and followed up until 36 weeks postpartum 
  




Table 4 Characteristics of meta-analyses 
Authors Study details 
 Country & time Inclusion criteria Exclusion criteria 
  Mother Infant  
RCTs     
Taha et al 2010 [36] Malawi 
NVAZ trials 
 2000-2003 
HIV infected women were enrolled after obtaining informed 
consent.  
Infants were 
included for this 
analysis if they 
returned for follow-
up visit at 6-8 
weeks. 
 
Newell et al 2004 [37] 7 trials conducted in SSA 
Split geographically in 
analysis: east Africa 
(Tanzania & Kenya), west 
Africa (Côte d‘Ivoire)& 
South Africa 







Criteria not stated   
Observational     
Becquet al 2009 [38] 2 cohorts: 
Vertical transmission 
study**, South Africa 
Ditrame Plus ,Côte d‘Ivoire 
VTS 2001-2004 
Ditrame Plus 2001-2003 
Ditrame Plus: HIV infected women ≥18 years 
 
VTS: HIV infected women ≥16 years 
 
In this analysis 
breastfed infants 
who were HIV 
uninfected at or 
after 30 days 
included. 
 





Table 5 Quality measures: randomised controlled trials 
 ARVs 
Authors Follow-up Sample size Feeding Mothers Infants 
   Methods &definition Yes/No + regimens Yes/No + regimens 







BF only, no other fluids or food 
BF + other fluids, solid foods & 
non-human milk 
BF + other fluids, excl milk 
FF only, never BF 
 
ZDV: 34 weeks gestation 
to deliver & sdNVP 
ZDV until 1 month for all 
infants. Continued to 6 
months if infants BF. 
Kuhn et al 2009 [17] 
 
24 months ‘09: 661 dyads, 
still BF at 4mths 
infants 
EBF EBF until 4/12, only BM no other 
foods or liquids 
sdNVP sdNVP 
Kuhn et al 2005 [15]  ‘05: 620 HEU 
infants (f/up until 
4/12) 
Kuhn et al 2007 [16]  ‘07:734 infants 
HIV-free to 6 
weeks & still BF 
at 4mths 
Kuhn et al 2010 [19]  ‘10:958 dyads, 
749 with last 
PCR negative 
Arpadi et al 2009 [18]  Arpadi ‘09: 593 
HEU 
 
Coutsoudis et al 2001 
[20] 
15 months 551 dyads Informed 
choice 
BF -394 
FF – 157 
 
Ever BF including  EBF (EBF for 
≥ 3months) and MBF (EBF < 3 
months or no EBF) 
FF: never BF 
No No 
Nduati et al 2000 [21] 24 months 401 dyads FF-204 
BF-197 
FF: complete avoidance of BM 
BF: any use of BM 
No No 
Mbori-Ngacha et al 2001 
[22] 










Authors Follow-up Sample size Feeding Mothers Infants 
   Methods &definition Yes/No + regimens Yes/No + regimens 





Only BM, no other liquids, milks 
or solid foods 
BM predominant source, but 
non-milk liquids were also given 
BM, non-human milk, and solid 
or semi-solid food. 
 
No No 
Muhangi et al 2013 [25] 18 months 1502 infants 
1380 unexposed 
122 HEU 
BF Looked at early weaning – 
defined as introduction of cow‘s 
milk before 6 weeks of age 
 
sdNVP sdNVP 











 HAART became 
available (131 mothers 
started during the follow-
up period) 
sdNVP & bd ZDV: 1 week 
(control) 
NVP for 14 weeks + control 
NVP & ZDV for 14 weeks + 
control 
Homsy et al 2010 [28] 18 months 
(median) 
118 infants EBF Only BM HAART: 3TC, D4T & 
NVP 
sdNVP/ZDV added 2005 
 
Natchu et al 2012 [29] 60 months 585 infants EBF BM only, without any other 
liquid, milk or solids 
No No 
sdNVP: single dose nevirapine; NVP: nevirapine ZDV: zidovudine; 3TC: lamivudine; D4T: stavudine; HAART: highly active antiretroviral therapy; mths: months; bd: twice daily 




Table 6 Quality measures: observational studies 
 ARVs 
Authors Follow-up Sample size Feeding Mothers Infants 
   Methods & definition Yes/No + regimens Yes/No + regimens 







BF/MBF  Definitions not provided sdNVP/ART sdNVP 
Bobat et al 1997[31] 2924 child-
months 
follow up 












Only  BM from birth 




Coovadia et al 2007 [32] 
 
Coovadia 


















Only BM from birth, no other 
liquids or solids 
BM & non-human  milk, other 
liquids or solids 
Non-human milk, exclusion of 
BM, with or without other liquids 
or solids 
sdNVP sdNVP 
Patel et al 2010 [33] Patel 













85 infants of HIV-
infected mothers 
who appeared 
uninfected   
184 infants of HIV-













Authors Follow-up Sample size Feeding Mothers Infants 
   Methods & definition Yes/No + regimens Yes/No + regimens 
Goga et al 2012 [35] 36 weeks 665 HIV-infected 
mothers & infants 
218 HIV-uninfected 








BM only, prescribed medication 
allowed 
BM and/or FF and other foods 
(solids/liquids) 
FF only 
FF and other foods 
(solids/liquids) were provided 
sdNVP sdNVP 
sdNVP: single dose nevirapine; mths: months 
BF: breastfeeding, BM: breast milk, EBF: exclusive breastfeeding, MBF: mixed breastfeeding, PaBF: partial breastfeeding, PrBF: predominant breastfeeding, FF: fofmula feeding, EFF: exclusive formula feeding, MFF: mixed 
formula feeding
 
Table 7 Quality measures: meta- analyses 
 ARVs 
Authors Follow-up Sample size Feeding Mothers Infants 
   Methods & definition Yes/No + regimens Yes/No + regimens 
RCTs       




Newell et al 2004 [37]  - 3468 infants Ever BF 
Never BF 
 
 - No No 
Observational       











VTS:  sdNVP 
 
Ditrame Plus: sdNVP& 
ZDV ± 3TC 
sdNVP 
sdNVP: single dose nevirapine; NVP: nevirapine ZDV: zidovudine; 3TC: lamivudine; mths: months 




2.1 Study design 
Design 
Randomised controlled trials, observational studies and meta-analyses were included in this 
literature review. Randomised controlled trials mostly aimed to investigate the efficacy of 
ARVs for PMTCT while in earlier research the risks associated with different feeding 
modalities in the absence of ARVs were assessed. As the importance of exclusive 
breastfeeding (EBF) as opposed to mixed feeding (MF) was realised, trials investigated 
feeding modality with the use of ARVs. However, adherence to assigned randomisation and 
not returning for follow-up is a concern. Cohort studies provide a more ‗true to life‘ scenario 
compared to trials, particularly as infant feeding is self-selected, and the realities of ARV 
access are brought to the fore, however confounding is almost inevitable as patients 
selecting a particular feeding modality are likely to differ with respect to a number of 
characteristics from those selecting a different feeding method. Cohort studies too, have the 
concern of participants not returning for follow-up. This loss to follow-up is important to 
consider as it introduces selection bias, thus skewing results. The meta-analyses included in 
this literature review have combined data from trials [36, 37] and cohort studies [38]. The 
meta-analyses presented here pooled and re-analysed data from different studies as 
opposed to just interpreting the results of different studies. 
Formula feeding, with complete avoidance of breastfeeding, was adopted  as the feeding 
method of choice for HIV exposed infants in developed countries many years ago [11].  
Once this recommendation was adopted in developed countries, investigating the effects of 
feeding choice on HIV transmission became a challenge. Two trials, one in Kenya [21–23] 
and one in Botswana [14] randomised feeding modality. However, as knowledge expanded 
regarding virus transmission via feeding, and other related effects of not breastfeeding were 
considered, the nature of studies investigating infant feeding changed. Studies started to 





breastfeeding [14, 21]. In the case of one of the Kenyan trials, the duration of follow-up was 
reduced to 6 months from 24 months approximately 1 year before the trial closed, and all 
mothers who were randomised to the breastfeeding arm were advised to stop breastfeeding 
and switch to infant formula (April 1998). It must be noted that this trial was conducted prior 
to the availability of ARVs. Additional characteristics of this trial, and other trials evaluated, 
are detailed in table 1.  
The observational studies included in this literature review are all cohort studies 
(retrospective and prospective). The characteristics of these cohort studies are described in 
table 2. 
Length of follow-up 
The majority of studies in this review, whether a trial, cohort study or meta-analyses have 
follow-up periods of 18 to 24 months [14–19, 21–26, 28, 30, 33, 34, 36, 38]. Two cohort 
studies had a follow-up duration of less than 1 year [32, 35] and one study, a trial, had a 
follow-up duration through to 5 years of age, although  the analysis included was a 
secondary analysis focussing on mortality risk of infants during the first 6 months of life [29].  
Availability of ARVs 
Seven studies were conducted prior to the availability of ARVs – whether as prophylaxis or 
triple therapy [20–24, 29, 37, 39]. Eight studies only had ARVs available as prophylaxis [14–
19, 25, 32–36, 38] and all remaining studies (n=3) used a combination of prophylaxis and 
triple therapy as triple therapy became available [26, 28, 30].  
 
2.2 Sample size 
 
The sample sizes ranged from 93 [31] to over 2 000 HEU infants [24, 37]. However, the 




PCR testing available to confirm HIV status. One study did not have ethical approval to test 
infant HIV status so they assumed infants were uninfected if still alive at 2 years of age [34]. 
It is possible that HIV infected infants survived to 2 years of age without showing symptoms 
of HIV infection, thus growth (only growth through to 16 weeks was assessed) in the HEU 
infants in this study population may have been underestimated, as HIV infected infants could 
have been included in this group.  
This difference in sample size, and testing infants to confirm HIV status reflects the difficulty 
in studying these infants. The change in studies over time, reflecting availability of testing 
methods and increased knowledge on HIV transmission and the use of ARVs, also illustrates 
this difficulty.  
3. Results from studies 
 
The results from the studies included in this review are detailed in tables 8 through 10 for 
trials, observational studies and meta-analyses respectively. Where these tables report 
measures of association, the second variable is the reference category unless otherwise 
specified. Some trials analysed results based on a cohort or included a nested cohort. As 
these studies were originally designed as randomised control trials, their results are included 
in table 8. The results about feeding, growth, transmission and morbidity are discussed in 




Table 8 Results from randomised controlled trials 
Authors Outcome Comparison Measure of Association 95% CI  (p-value) CI ratio (difference)* 
Thior et al 2006 [14] HIV transmission BF vs. FF  1.65# 1.07, 2.55 (0.02) 2.38 
 
Kuhn et al 2005 [15] Mortality Maternal CD4 < 350 cells/µl vs. CD4 ≥ 350 
cells/ µl 
Maternal death <4 months 


















Maternal CD4 < 350 cells/ µl 









Weight (kg);1 week – 4 
months 
Birth weight (per 100g increase) 
Maternal death < 4months 











Kuhn et al 2007 [16] HIV transmission Non-EBF vs. EBF 
Maternal CD4 < 350 cells/ µl vs. CD4 ≥ 350 
cells/ µl 


















Within Intervention group (adherent) 







1.04, 5.54 (0.035) 
 





Kuhn et al 2010 [19] Mortality Intervention: 
BF cessation 
























Arpadi et al 2009 [18] 
 
WAZ (4mths – 15mths) 
 
BF cessation 
High maternal VL (≥100 000 copies/ml) 














Coutsoudis et al 2001 
[20] 
HIV transmission EBF vs. MF 














Authors Outcome Comparison Measure of Association 95% CI  (p-value) CI ratio (difference)* 











FF vs. BF 
Birth WAZ per 1 unit increase   
FF vs. BF 
Birth LAZ per 1 unit increase 
FF vs. BF 









0.63, 1.77 (0.84) 
0.27, 0.53 (<0.001) 
0.69, 1.50 (0.94) 
0.40, 0.57 (<0.001) 
0.67, 2.68 (0.40) 















Never BF vs. Ever BF 
Birth WAZ per 1 unit increase 
Never BF vs. Ever BF 
Birth LAZ per 1 unit increase 
Never BF vs. Ever BF 









0.67, 1.92 (0.64) 
0.28, 0.53 (<0.001) 
0.64, 1.38 (0.74) 
0.41, 0.57 (<0.001) 
0.71, 2.73 (0.33) 








Illiff et al 2005 [24] HIV transmission At 6 months 
MBF vs. EBF 
PrBF vs. EBF 
Maternal CD4 < 350cells/µl  vs. CD4 >500 
cells/µl   
Maternal CD4 <200 cells/µl vs. CD4 > 500 









0.98, 16.61 (0.05) 
0.59, 11.67 (0.20) 
1.63, 6.11 (0.0006) 
 








Muhangi et al 2013 
[25] 
12 months of age 





HEU vs. Unexposed 
Birth weight < 2500g 
Early weaning 









1.32, 4.09 (0.006) 
1.62, 5.53 (0.001) 
1.16, 2.71 (0.010) 






Stunting < -2SD LAZ 
 
HEU vs. Unexposed 
Birth weight < 2500g 
Early weaning 






0.92, 2.61 (0.107) 
1.86, 5.29 (<0.001) 
0.84, 1.72 (0.314) 






Wasting < -2SD WLZ 
 
HEU vs. Unexposed 
Birth weight < 2500g 
Early weaning 






0.37, 2.52 (0.947) 
0.93, 5.71 (0.097) 










Authors Outcome Comparison Measure of Association 95% CI  (p-value) CI ratio (difference)* 
Taha et al 2011 [26]  
WAZ ≤ 2 









1.05, 1.79 (0.02) 
 0.97, 1.83 (0.07) 


















1.37, 2.11 (<0.0001) 
1.28, 2.14 (0.0001) 
1.26, 2.43 (0.0008) 
 






Homsy et al 2010 [28] Mortality Months of total BF (or age at weaning; 
continuous variable) 
 






0.57, 0.87 (0.001) 
 
 






Natchu et al 2012 [29] Mortality EBF (time dependent variable) 0.51# 0.28, 0.93 3.32 
*Confidence interval (CI) ratio or difference reflects measurement precision. The CI ratio is the UCL/LCL and is used for all logistic regression models. The CI difference is the UCL – LCL and is used for linear regression models. #Hazard ratio 





Table 9 Results from observational studies 
Authors Outcome Comparison Measure of 
Association 
95% CI  
 (p-value) 
CI ratio (difference)*  
Landes et al 2012[30] Mortality HIV exposed vs. Unexposed 





1.1, 7.2 (0.03) 
1.0, 6.3 (0.05) 







Bobat et al 1997 [31] HIV transmission EBF vs. EFF 1.63¥ 0.71, 3.76 5.30  






















Coovadia et al 2007 
[32] 
 
HIV transmission MBF vs. EBF (HEU) 
 
In EBF infants 
Maternal CD4 < 200 cells/µl vs. 
CD4 > 500 cells//µl 










0.66, 3.69 (0.308) 
 
 
2.35, 6.12 (<0.001) 
 
 










Patel et al 2010 [33] WAZ Exposed vs. Unexposed infants 
(birth weight >2500g and CD4 
>500cells/µl) 
Birth weight < 2500g 
Infected vs. HEU infants 
Ever BF 
Maternal CD4 200 -499 cells/µl 












-2.21, -1.81 (<0.001) 
-0.29, -0.10 (<0.001) 
0.011, 0.086 (0.01) 
-0.27, -0.034 (0.01) 

















Authors Outcome Comparison Measure of 
Association 
95% CI  
 (p-value) 
CI ratio (difference)*  

















0.66, 0.85 (<0.001) 
 
 







LAZ 6 weeks 
Birth WAZ 












0.49, 0.73 (<0.001) 
-0.74, -0.01 (0.046) 
 
 









Goga et al 2012 [35] HIV transmission or 
death 
vs. No BF, Paarl     
Rietvlei 
No BF 




















































*Confidence interval (CI) ratio or difference reflects measurement precision. The CI ratio is the UCL/LCL and is used for all logistic regression models. The CI difference is the UCL – LCL and is used for linear regression 





Table 10 Results from meta-analyses 
Authors Outcome Comparison Measure of Association 95% CI  (p-value) CI ratio (difference)* 
RCTs      




Not BF vs. BF -1.08‡ 
-0.62‡ 
-0.64‡ 
-1.16, -0.99 (<0.001) 
-0.73, -0.52 (<0.001) 




Newell et al 2004 [37] Mortality Ever BF vs. Never BF 
Maternal death 





0.50, 1.75 (0.84) 
1.92, 6.96 (0.0001) 





Observational      
Becquet al 2009 [38] HIV transmission BF < 6mths vs. BF >6mths 
Solids ≤2months  




0.9. 3.4 (0.06) 
1.1, 8.0 (0.04) 




*Confidence interval (CI) ratio or difference reflects measurement precision. The CI ratio is the UCL/LCL and is used for all logistic regression models. The CI difference is the UCL – LCL and is used for linear regression 





Feeding definitions  
The WHO has defined the different feeding modalities (as outlined in the protocol, table 3). It 
is against these definitions that feeding across studies will be assessed.  
The studies included in this review emphasised that mixed feeding is most commonly 
practised, whether from birth or shortly thereafter [14, 20–24, 29, 31, 35, 37].  Assessing 
feeding is inherently difficult and is usually based on self-reports [15–17, 19, 20, 28, 29, 31, 
32, 35, 37]. Even in studies where feeding was randomised [14, 21–23], compliance was 
based on maternal reports. These may be strongly influenced by social desirability bias. The 
inconsistencies with feeding definitions and the difficulties in ensuring that feeding modality 
can be defined as per the WHO feeding classifications limits the comparability across 
studies where feeding and growth, morbidity or mortality were examined. 
For example, one study had grouped infants who were mixed fed with formula fed infants 
and compared this group to  exclusively breastfed infants [31]. Other studies had exclusive 
breastfeeding (EBF) defined for shorter periods compared to the 6 months encouraged by 
the WHO [15–20] although one was the ZEBS trial where the aim was to assess the impact 
of shortened duration of EBF to 4 months on MTCT and other infant outcomes. Owing to this 
complexity, many studies compared infants that had ever been breastfed to infants that had 
never been breastfed (formula fed), thus losing the ability to examine the impact of duration 
of breastfeeding, particularly EBF, on growth, morbidity and mortality.  
Feeding modality compliance 
In addition to the difficulty in defining feeding modality, compliance with a feeding modality 
whether it was one selected by the mother herself or one to which she was randomised, is 
frequently low.  For example, compliance to randomisation in the Kenyan trial [21] was 70% 
in the formula feeding arm and 96% in the breastfeeding arm. Compliance in the 





months respectively. EBF had even lower rates of compliance – 83% at 6 weeks, with a 
large drop by 3 (62%) and 6 (9%) months [21]. When specifically looking at HEU infants [23], 
15% of breastfed and 10% of formula fed infants were receiving solids by 3 months of age 
(median age of introduction 4.5 months).  In the Mashi trial [14], compliance in the formula 
feeding arm was reasonably high (93%), however, like the Kenyan trial, compliance in the 
breastfeeding arm decreased over time. In the Mashi trial mothers in the breastfeeding arm 
were encouraged to practice EBF. Compliance to EBF was 57%, 31.3% and 17.5% at 1, 3 
and 5 months respectively. At 3 months nearly 50% of those in the EBF arm were practising 
mixed feeding (MF) and by 5 months this had increased further to 75%.  
In a Tanzanian study, the practice of EBF was also poor, with only 30% of infants exclusively 
breastfed for longer than 3 months [29]. A South African study found that 28.5% of mothers 
never breastfed their infants [20], and in a pooled analysis 51% of South African infants had 
not been breastfed compared to 2% of infants in east and west Africa [37]. A Ugandan study 
found that, where mothers had been counselled to practice EBF for 3-6 months, 92% of 
mothers practised EBF for a median duration of 4 months, stopping at a median age of 5 
months. By 6 months, 48% had been weaned from BF completely, 25% were still EBF and 
20% were MF [28].   
In  studies conducted in South Africa, the proportion of MF infants ranged from 15.4% MF at 
6 months [32] to  48% partially BF and 52% predominantly BF by 12 weeks of age [35] even 
though breastfeeding initiation was high (95%) in the latter study. Partial and predominant 
BF are sub-categories of mixed BF as detailed in the WHO feeding definition table (table 3 in 
the protocol). It is important to note that the study conducted by Coovadia et al [32] was an 
intervention cohort, with mothers receiving frequent support (antenatal counselling and 
regular postnatal support) with infant feeding, regardless of which modality was chosen 
although mothers were encouraged to exclusively breastfeed. In contrast, Goga et al looked 




the results was similar to a study conducted early in the HIV/AIDS pandemic where 57% of 
infants were MF [31] .  
A major benefit of the study conducted by Goga et al is that they found a differential in 
breastfeeding rates, dependent on the resource capacity of the study site [35]. In this study, 
an urban site had a greater number of infants initiated on FF (75%) compared to the peri-
urban (58%) and rural (21%) sites. Resource capacity also had an impact on HIV 
transmission, as discussed below. 
Introduction of solids 
Although never breastfed leads one to think that formula feeding was exclusive, this may not 
necessarily be the case. Mothers may formula feed, and not breastfeed, their infants but still 
introduce solids or other non-milk liquids too early. This too comprises mixed feeding as 
defined by the WHO. Goga et al defined formula feeding in combination with other foods 
(liquids and solids) as mixed formula feeding and in their study 67% of HIV infected mothers 
who had never breastfed their infants (47% of HIV infected mothers) were practising mixed 
formula feeding by 3 weeks of age.  
3.2 Growth 
Feeding and growth 
Growth was assessed by studies, most frequently,  by looking at z-scores for weight-for-age 
(WAZ), length-for-age (LAZ) and weight-for-length (WLZ) [18, 22, 23, 25, 30, 36]. Mbori-
Ngacha et al found that after adjusting for HIV infection, infants who were breastfed had a 
better nutritional status (WLZ) compared to formula fed infants, particularly during the first 6 
months of life. During follow-up, 7% of breastfed HEU infants and 11% of formula fed HEU 
infants were malnourished, and found to have WLZ < -2SD [22]. In the retrospective cohort 
study conducted by Landes et al, in which all infants received some BM, 4% of HEU had a 





In studies focussing on growth among HEU infants only, not breastfeeding was associated 
with worse growth (WAZ, LAZ or WLZ) outcomes [15, 23, 26, 33, 36]. In the ZEBS trial 
analysis specifically focussing on growth among HEU infants a sharp decline in WAZ was 
observed in all infants between the ages of 4.5 and 15 months. In infants who were not 
weaned abruptly at 4 months but continued to BF, the decline in WAZ was lessened [18]. As 
randomised, infants assigned to early cessation had a mean (± standard deviation) WAZ of -
0.61 ± 0.07 at 4 months, while the control group, who continued breastfeeding, had a mean 
WAZ of -0.55 ± 0.07. However compliance with abrupt weaning was low and a per protocol 
analysis showed that infants who actually stopped breastfeeding abruptly had a mean WAZ 
of -0.89 ± 0.34 (14.3% <-2 SD WAZ), and infants who continued breastfeeding had a mean 
WAZ of -0.57 ± 0.05 (9.4% <-2SD WAZ) at 4 months of age. By 6 months of age, infants 
who stopped breastfeeding (as practised) had a mean WAZ of -0.78 ± 0.08 (13.1% <-2SD 
WAZ) and infants who continued breastfeeding had a mean WAZ of -0.61 ± 0.06 (10.6% <-
2SD WAZ). Thus, it is clear that growth slowed over time, but the effect was somewhat 
ameliorated by breastfeeding.  
Early weaning, defined as the introduction of cow‘s milk at or before 6 weeks of age was 
also found to negatively affect growth [25]. In the secondary analysis conducted by McGrath 
et al [23], both an intention to treat (ITT) and per protocol (PP) analyses were conducted due 
to poor compliance to feeding randomisation as discussed previously. In the ITT and PP 
analyses the results were fairly consistent and showed that not breastfeeding had a negative 
impact on growth (particularly WAZ and WLZ), although like in the ZEBS study this effect 
may be attenuated in the ITT analysis due to poor compliance. Little difference was found in 
either the ITT or PP analysis when looking at the effect of feeding on stunting; thus, neither 
formula feeding nor breastfeeding was protective against stunting and other factors may play 
a greater role in the risk of being stunted. Stunting is indicative of chronic under-nutrition 




infections may be of greater importance. Breastfeeding cessation was also found to have a 
negative impact on all growth parameters [18]. 
Birth anthropometry, maternal factors and growth 
Infant birth weight has an impact on postnatal growth as well – a higher birth weight (and 
other birth anthropometric measures) is associated with higher post-natal anthropometric z-
score whereas a birth weight  <2 500g has a negative effect on postnatal z-scores although 
growth velocity is frequently faster in this group due to catch-up growth [15, 18, 23, 25, 33]. 
In the ZEBS trial, one analysis looked at the effect of actual birth weight on growth [15] as 
opposed to z-scores, with the study examining the effect of each 100g increase in birth 
weight. In the analysis looking at growth (specifically mean postnatal WAZ by birth weight) in 
HEU infants in the ZEBS trial, at 1 month of age, low birth weight (LBW) infants had a mean 
WAZ of -2.19, improving to -1.65 by 6 months of age. Normal weight infants had a mean 
WAZ of -0.33 at 1 month of age, decreasing to -0.58 by 6 months of age [18]. Although 
infants with a normal birth weight had a greater WAZ at 6 months of age compared to low 
birth weight infants (p <0.0001) this was mostly due to a higher weight at birth and 1 month 
of age, with growth actually being better among LBW infants, compared to normal weight 
infants. In the Kenyan trial, z-scores were classified as <-2SD for WAZ, LAZ and WLZ and 
not analysed as a continuous variable over time or separated by LBW and normal birth 
weight. However, the authors reported a non-significant increase in both WAZ and WLZ 
during the first 6 months, followed by a decline in weight in both BF and formula fed (FF) 
infants. No differences in the rate of change in WAZ or WLZ were found by feeding modality 
in either the PP or ITT analyses [23].  
The VTS study found that the change in WAZ by birth weight with age (in weeks) was   -
0.0037 (95% CI -0.0055; -0.0017 p <0.001) for normal weight infants and 0.02 (95% CI 
0.014; 0.027 p <0.001) for LBW infants [33]. Once again the results show faster growth, over 




Maternal factors, particularly death 4 months after delivery [15] and advanced (low CD4 
count or high viral load)  maternal disease [18, 25, 33], were also associated with worse 
infant growth over time. Lastly, Muhangi et al found that HEU infants were at increased odds 
of poor growth compared to unexposed infants [25].  
In a Zambian study looking at growth and HIV the authors unfortunately did not have ethical 
approval to test infant HIV status [34]. The authors tried to work around this limitation by only 
assessing growth information of infants of infected mothers who could be traced, and thus 
were still alive between the ages of 2-4 years. Once again, birth anthropometry was an 
important determinant of growth, while in this study population maternal HIV status only 
seemed to influence LAZ at 6 weeks of age. 
3.3 Morbidity and mortality 
Feeding modality and mortality 
The risk of mortality in breastfed and formula fed infants was not consistent across trials 
investigating the effect of feeding modality on death. The Kenyan trial found that mortality 
was similar between BF and FF infants [21]. In a subsequent analysis, Mbori-Ngacha et al 
[22] found FF to be 28% protective against the combined outcome of death and HIV 
transmission. The authors also looked at a subset of infants who remained uninfected for the 
duration of the follow up period. The infants in the BF arm had a cumulative mortality rate of 
8.1% compared to the FF arm at 10% (p=0.59).  
The pooled analysis of seven studies by Newell et al [37] found that mortality did not differ 
significantly between ever and never BF infants while Natchu et al found an inverse 
relationship between EBF and mortality, with EBF associated with lower mortality, between 
birth and 5 months of age [29]. No information was provided on MF. In the Mashi trial, EBF 
infants had a lower risk of mortality compared to FF infants through to 7 months of age [14]. 
The Ugandan study had similar results to the Mashi trial, finding BF to be protective against 




a 6-fold increased risk of mortality compared to infants breastfed for more than 6 months 
[28]. 
Maternal factors, birth weight and mortality 
Maternal death and advanced disease also increased the risk of infant mortality [15, 30, 37]. 
Kuhn et al found a differential effect between feeding modality and mortality depending on 
the severity of maternal disease as well as infant birth weight <2 500g [19]. There was an 
increased hazard of mortality in those who adhered to the intervention i.e. stopped 
breastfeeding at 4 months of age. The increased hazard associated with weaning was 
greater in those with a maternal CD4 count >350 cells/µl compared to those with lower CD4 
cell counts. The control group (continued BF) also showed an increase in mortality once 
breastfeeding was stopped. Landes et al also found that HIV exposure and a birth weight <2 
500g increased the risk of death among infants [30].  
Feeding modality, maternal factors and morbidity 
In the Zambian trial, no difference was found between feeding modalities for the incidence 
rates of diarrhoea or pneumonia when infants were stratified by infection status [22]. 
McGrath et al [23] found that an episode of diarrhoea within the past month, meant a 2-fold 
increased risk of wasting (WLZ <-2SD) compared to infants who had not had diarrhoea 
(similar in both the ITT and PP analyses). 
Studies were in agreement that advanced maternal disease increased risk of HIV infection 
and other morbidities, including hospitalisation [15, 19, 24]. The PEPI-Malawi trial found that 
for general morbidities, breastfeeding was protective at 6-9, 9-12 and 12-15 months of age 
[26].  
Bobat et al examined morbidity, specifically otitis media, diarrhoea and pneumonia in relation 
to feeding modality [31].  No incidence of morbidity was seen in FF infants, therefore in order 
to calculate a risk ratio the authors combined FF and MF infants and compared them to BF 




Africa, before the use of ARVs and current knowledge on mixed feeding. Instead of grouping 
MF and FF infants, the authors should rather have compared morbidity between MF and 
EBF infants. 
Nuanced feeding modality duration and HIV transmission 
When looking at morbidities and risk of HIV transmission, cohort studies provided an 
additional nuance by including feeding type and duration [31, 32, 35, 38] 
In a non-randomised intervention cohort conducted in South Africa [32] an increased risk of 
infection was found for mixed feeding, specifically looking at infants who were HEU at 6 
weeks of age. Advanced maternal disease and a birth weight of <2500g were also 
associated with an increased risk of infection.  
In a pooled analysis of a South African and west African study, Becquet et al [38] found an 
increased risk of transmission among infants breastfed for >6 months, and found that this 
risk increased by 1% (CI ratio 3.40) for each additional month of BF beyond 6 months. It is 
important to take into account that in this pooled analysis the PMTCT regimens differed 
between the two studies – the South African study (study one conducted by Coovadia et al, 
mentioned above) only provided single dose nevirapine, while the Ditrame Plus study used 
zidovudine and/or lamivudine together with single dose nevirapine. 
Resource availability, HIV transmission and mortality 
Goga et al [35] showed that the risk of a combined end point of either HIV infection or death 
by 9 months of age, by feeding modality, was site dependent. Paarl, a well-resourced site 
with an infant mortality rate (IMR) of 40/1 000, had a lower risk of either transmission or 
death if infants were exclusively formula fed. In contrast, the two sites with high IMRs 
(Rietvlei 99/1 000 and Umlazi 60/1 000) had lower risk of transmission or death if infants 
were exclusively breastfed and weaned early. When this study was conducted, single dose 




4. Study comparability 
 
Many studies where HEU infants are included as study subjects focused mainly on either 
HIV transmission [14–17, 20, 24, 31, 32, 38], death [19, 26, 28–30, 37], or a combined end 
point [35]. The health outcomes among HEU infants only came to the fore once PMTCT 
programmes were proven to be successful.  This includes the growth of HEU infants.  
The Kenyan and Mashi trials were the only studies in which feeding modality was 
randomised antenatally [14, 21–23]. In all other studies, feeding was either standard for a set 
time followed by randomisation to continued breastfeeding for as long as the mother decides 
or abrupt cessation [15–19] or feeding modality was the mother‘s decision, based on 
informed choice. Furthermore, regardless of feeding modality decided upon, the recorded 
compliance to assigned method or method of choice was always based on self-report. The 
lack of an objective measure to assess feeding modality is one of the inherent difficulties in 
investigating infant feeding.  
The results tables contain confidence interval (CI) ratios or differences as these are a better 
indication of measurement bias than the CI or the p-value [42]. The CI ratios reflect 
measurement precision, and in studies where these ratios (or differences) were particularly 
large, it was related to small sample size. For instance, in the Kuhn et al study [15], very few 
infants ceased breastfeeding before 4 months (36 vs. 584 still breastfeeding at 4 months), 
had a birth weight of <2 500g (86) and had mothers die within 4 months of delivery (16), thus 
explaining the size of the CI ratios. Another example is the analysis where McGrath 
investigated growth in HEU infants - the CI ratios indicate that measurement was fairly 
precise and that there is an increased risk of being underweight or wasting when 
breastfeeding is avoided despite a p-value of >0.05. The p-value is an arbitrarily chosen 




Lastly, it is worth mentioning that the rates of EBF reported in the intervention cohort study 
was higher than reported in all studies [32]. As the authors mentioned, this is related to the 
intensive counselling the mothers received on infant feeding, both antenatally and 
postnatally. Many studies did not provide intensive support for EBF even if mothers were 
given the information to make an informed choice on feeding modality. Rates of EBF were 
generally low in studies where EBF was investigated [20, 35], with a rapid decline over time 
emphasising the challenges mothers face sustaining EBF for 6 months as advised by the 
WHO. 
4.1 Study concerns 
 
In this review, results from trials that were not originally designed to investigate growth or 
feeding were included [20, 24, 25]. Thus the results of these studies, although included in 
the trials table, represent cohort studies as subjects were a sub-group of the entire trial 
sample. Despite not originally designed to investigate growth or feeding of HEU infants, 
these studies provided much needed information on HEU infants.   
In a study conducted during the early stages of the HIV/AIDS pandemic in South Africa, the 
authors did not report any details on the introduction of solids [31]. The authors mentioned 
that infants would have received complementary foods for varying periods but median age of 
introduction was not assessed. This is important, as early introduction of non-milk feeds 
constitutes mixed feeding and the authors mentioned the overall median duration of EBF for 
the whole group was 5 months, with the median duration among mothers practising EBF as 
12 months. This contradicts the WHO feeding definitions as EBF is only supposed to occur 
for the first 6 months when the introduction of solids or complementary foods for the 






When looking at South Africa, breastfeeding rates, particularly EBF rates, are low. In the 
study conducted at PMTCT sites, Goga et al also included uninfected mothers and found 
that mixed feeding was the norm for the uninfected population too. Ninety-five percent of 
uninfected mothers initiated breastfeeding, and although by 3 weeks 93% were still 
breastfeeding, this decreased to 73% and 66% by 12 and 36 weeks respectively. EBF rates 
were even lower; 17% and 3% at 3 and 12 weeks respectively [35]. 
Breastfeeding is important for infant health, whether infants are HIV-exposed or unexposed, 
and longer duration of breastfeeding should be supported for all mothers. HIV infection in 
mothers increases the complexity of generic feeding advice; these mothers require more 
intensive assistance and advice in order to maintain the health of their infants, and keep 
them uninfected. Breastfeeding, infant growth and infant morbidity are interlinked as 
evidenced by the studies included in this review.  
With the success of PMTCT programmes, the focus is slowly shifting from merely treating 
HIV-infected infants, but keeping HEU infants uninfected and optimising their health 
outcomes, including growth, too. The health needs of HEU infants are not well known, and 
the long term consequences of both in utero and breast milk exposure of ARVs are also not 
known, but research in the field continues. Key to this, is describing the HEU cohort, and 
maintaining follow-up for as long as possible, particularly as most studies stop follow-up 
around 24 months of age.  
As the number of infants who are exposed yet uninfected will increase in number, future 
research should endeavour to understand baseline characteristics of these infants, their 
impact on future growth and health outcomes, and how they compare not only to exposed 




unexposed infants, without which the health needs and outcomes of HEU infants in 
comparison to the general infant population cannot be adequately understood. This includes 
examining growth outcomes, and whether or not HEU infants fare worse or are on par with 
unexposed infants for a given population. Furthermore, feeding is an integral component of 
child health, and novel ways of confirming reported compliance are needed to make it less 
subjective. 
It is important to remember, that most studies looking at feeding did so in a fairly controlled 
environment. As PMTCT programmes continue to succeed, the coverage and use of ART 
will increase. Investigating the effects of feeding and maternal ART in a ‗real world‘ setting is 
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Growth of HIV-exposed uninfected infants in the first 6 months of 
life in South Africa: the IeDEA-SA collaboration 
Abstract 
Background: HIV-exposed uninfected (HEU) infants are a growing population in southern 
Africa especially with the increasing coverage of more effective prevention of mother-to-child 
transmission (PMTCT) antiretroviral therapy regimens. This study describes the 
characteristics of South African HEU infants, investigates factors impacting birth weight and 
assesses their growth within the first 28 weeks of life. 
Methods: This is a retrospective cohort based on routine clinical data provided to the 
International Epidemiologic Databases to Evaluate AIDS, Southern Africa (IeDEA-SA) 
collaboration. Linear regression assessed factors affecting birth weight-for-age z-scores 
(WAZ) while growth (longitudinal WAZ) was assessed using mixed effects models. 
Results: The growth of 2621 HEU infants was assessed. The median birth WAZ was -0.65 
(IQR -1.46; 0.0) and 51% were male. The feeding modalities practised were as follows: 0.5% 
exclusive breastfeeding, 7.9% unknown breastfeeding exclusivity, 78.6% mixed 
breastfeeding and 10.6% formula feeding. Mothers with a CD4 <200 cells/µl delivered 
infants with a lower birth WAZ (adjusted ß -0.253 [95% CI -0.043; -0.072], p = 0.006) 
compared to mothers with a CD4 ≥500 cells/≧l. Similarly, mothers who did not receive 
antiretroviral (ARVs) drugs delivered infants with a lower birth WAZ (adjusted ß -0.49 [95% 
CI -0.78; -0.20], p = 0.001) compared to mothers who received antenatal ARVs. Antenatal 
maternal ARVs and CD4 cell count did not have an effect on postnatal growth. Exposure to 
breast milk positively influenced growth, albeit the effect was small. Infants with a birth 
weight <2 500g (ß 0.069 [95% CI 0.061; 0.078], p <0.0001) experienced faster growth within 




Conclusion: Less severe maternal disease and the use of ARVs positively impacts birth 
weight in this cohort of South African HEU infants. Mixed feeding was common and any 






HIV-exposed uninfected (HEU) infants are a growing population in sub-Saharan Africa, 
particularly with increasing coverage of more effective prevention of mother-to-child  
transmission (PMTCT) regimens such as option B/B+, antiretroviral therapy (ART) for all 
pregnant and breastfeeding women either until cessation of breastfeeding or lifelong [1]. In 
2010, an evaluation of the South African PMTCT programme, where antenatal HIV 
prevalence was 32%, found the overall early HIV transmission rate (4-8 weeks postpartum) 
to be 3.5% [2] — indicating a large number of exposed but uninfected infants. More recently, 
antenatal HIV prevalence is 29.5% in South Africa and both effectiveness and coverage of 
PMTCT have improved [3]. 
Breastfeeding is known to transmit HIV, however its importance for infant nutritional status 
[4–8] and protection against morbidity [9] and mortality [10–13] is also well documented. In 
South Africa particularly, mixed feeding, defined by the World Health Organization (WHO) as 
a combination of breast milk and/or infant formula, other liquids and solids [14, 15], is 
common. In an evaluation of the South African PMTCT programme, 53% of HIV-infected 
mothers breastfed their infants, of which 42% practised exclusive breastfeeding (EBF) at 3 
weeks of age. By 12 weeks of age, however, only 18% of HIV-infected mothers who 
breastfed their infants were practising EBF. Among HIV-infected mothers who practised 
mixed breastfeeding (MBF) at 12 weeks of age, 48% and 52% of infants were partially 
(breast milk and non-nutritive and nutritive solids and liquids) and predominantly (breast milk 
and non-nutritive liquids) breastfed respectively [14]. Similarly, Coutsoudis et al found 57% 
of infants were mixed fed in a study conducted early in the HIV/AIDS pandemic, prior to the 
PMTCT programme [9], thus mixed feeding is widely practised in South Africa.  
Longitudinal growth is not only affected by feeding but by birth weight and maternal factors 
too. Infants with a higher birth weight have greater postnatal  weight-for-age (WAZ) over time 




first year of life is faster in LBW infants [4, 5, 8, 16, 17]. There have been conflicting findings 
with respect to the effect of feeding on growth. McGrath et al found no differences in the rate 
of growth between ever breastfed and formula fed infants, with WAZ increasing during the 
first 6 months after which they declined [8]. However, Malawian studies found that not 
breastfeeding was associated with both an increased risk of being underweight (WAZ <-2)  
as well as having lower weight-, length- and weight-for-length z-scores compared to infants 
who were breastfed [6, 7]. The Zambia Exclusive Breastfeeding Study found that among all 
HEU infants there was a decline in WAZ between 4.5 and 15 months, but that in infants who 
had continued breastfeeding at 4 months, the decline was lessened [16]. The early 
introduction of cow‘s milk (≤ 6 weeks of age) was also found to have a negative impact on 
growth [17]. The effect of feeding modality on growth may in part be context-dependent, and 
affected by the extent to which the AFASS (affordable, feasible, accessible, safe and 
sustainable) criteria for replacement feeding are met [14]. Maternal health also impacts child 
growth: infants of mothers with advanced disease (high viral load, ≥100 000 copies/ml, or 
low CD4 cell count, ≤350 cells/≧l) were found to have slower growth over time [5, 16, 17]. 
Many previous studies of growth in HEU were conducted outside South Africa, where 
breastfeeding practices and access to replacement feeding may be different, and prior to 
widespread availability of effective PMTCT regimens. The aim of this analysis was therefore 
to assess birth weight and growth within the first 6 months of life in HEU infants from two 
PMTCT cohorts in South Africa and examine the impact of maternal factors, including 
disease severity and the use of ARVs, and feeding modality. 
Methods 
Study design, setting and participants 
This was a retrospective cohort study based on routine data provided to the International 




collaboration. The IeDEA-SA cohort has been previously described [18, 19], although this is 
the first analysis of HEU infants. Two South African sites were included in this analysis 
namely McCord Hospital (MH), KwaZulu-Natal and Rahima Moosa Mother and Child 
Hospital (RMMCH), Gauteng. MH was a public-not-for-profit programme where a small 
patient co-payment was required at each visit, while RMMCH is a public hospital where care 
is provided at no cost to pregnant women and children ≤6 years old. Both facilities provided 
primary and secondary care. We included infants born from 2007 – 2013. Growth monitoring 
and promotion was provided based on standard practices at each facility. In South Africa, 
2008 guidelines on infant feeding advocated HIV-infected mothers exclusively breastfeed 
their infants unless replacement feeding met the AFASS criteria, in which case free infant 
formula was provided for 6 months [20, 21]. The 2010 PMTCT guidelines include ARV 
regimens. Women were eligible for lifelong ART (tenofovir (TDF) + lamivudine/emtricitabine 
(FTC) + nevirapine (NVP)) if they had a CD4 ≤350 cells/≧l or WHO clinical stage 3/4. 
Women not eligible for ART (CD4 >350 cells/µl or WHO clinical stage 1/2) received 
zidovudine (ZDV) from 14 week gestation followed by single dose NVP and ZDV during 
labour and TDF + FTC after delivery [22]. In 2011, the Tshwane declaration of support for 
breastfeeding was signed, ending the provision of infant formula for PMTCT in state 
facilities, like RMMCH [23]. MH continued the provision of infant formulae. 
We only included HIV-exposed uninfected infants with at least birth weight and one 
additional weight measurement within the first 28 weeks of life, with recorded maternal 
information. We excluded infants diagnosed as HIV-infected (n=126), mostly (97%) before 3 
months of age (8.7% diagnosed by 1 month, 89% between 1–3 months, 1.6% between 3–6 







The primary outcome was postnatal growth within the first 28 weeks of life which was 
assessed using WAZ only. We did not assess growth using length-for-age or weight-for-
length as length measurements were not available on all infants at all time points. Factors 
influencing birth weight were also assessed as birth weight impacts longitudinal postnatal 
growth.  
When assessing postnatal growth, birth weight was considered the baseline and follow-up 
visits with recorded weights were used to assess growth. WAZ were calculated using the 
WHO Child growth standards (igrowup, version 3.2.2 2011) package for Stata®. All statistical 
analyses were done using Stata® (StataCorp. 2011. Stata Statistical Software: Release 12. 
College Station, TX: StataCorp LP). 
Variables 
We collected data on the following maternal factors: parity (number of previous live births) 
for the index pregnancy (categorised as 0, 1 and ≥2); maternal age categorised as <18 
years (younger), 18-35 years and >35 years (older); antenatal CD4 cell count categorised 
into <200, 200-500 and ≥500 cells/≧l and maternal ARVs grouped into any ARVs 
(comprising unknown regimen, nevirapine (NVP) only, dual therapy and triple therapy), no 
ARVs and missing ARV information. Where maternal ARV regimen was changed during the 
pregnancy, we included the antenatal regimen closest to the delivery date.  
Infant variables collected included the following: sex, gestational age (based on palpation or 
date of last menstrual period) at delivery (categorised as term (≥ 37 weeks), preterm and 
unknown gestational age), birth weight (categorised as low (<2 500g) or normal (≥2 500g). 




never breastfed), unknown feeding and any breastfeeding (BF).  Any BF comprised EBF, BF 
with unknown exclusivity and MBF.  
Analysis 
Baseline characteristics between sites were compared using Wilcoxon rank-sum test for 
continuous variables and Chi-squared or Fisher‘s exact tests for categorical variables. 
We first assessed factors affecting birth weight using univariate and multivariate linear 
regression. We included gestational age, infant sex, maternal age and parity, and cohort in 
the model a priori and then examined the effect of maternal HIV disease (antenatal CD4 cell 
count and the use of ARVs) adjusted for the a priori variables. Univariate and multivariate 
analyses of the association between demographic, feeding and maternal factors affecting 
longitudinal postnatal growth were examined using mixed effects models with maximum 
likelihood estimation. A priori inclusions were similar to the linear regression model 
investigating birth weight outcomes. Feeding modality, infant age (continuous variable, in 
weeks) and birth weight were additional a priori inclusions. The model was then adjusted for 
maternal and disease-related factors. As growth is time dependent, interaction terms with 
infant age in weeks were included for all covariates. Covariates (including interaction terms) 
were included if the p-value was <0.1. As birth weight was a major determinant of postnatal 
growth, we conducted a sensitivity analysis limited to children with normal birth weight to 
examine the factors associated with growth in this subset of children. Owing to the nature of 
routine clinical data, not all variables were assessed at every visit or within the time period of 
this analysis. Mother-infant pairs were only included in the analyses for birth weight and 
growth if data on all variables in the models were complete, unless a missing category was 






There were 2948 dyads with a minimum of 2 visits, of these 327 (11.1%) were excluded as 
they did not have at least one visit after birth within the first 28 weeks of life.  

















324 McCord; 2318 Rahima Moosa 
 
Analysis restricted to ≤28 weeks 
A further 21 infants excluded – 1 
weight measure 
2948 HEU dyads 
Minimum 2 visits 
Cohort split: 
332 McCord; 2616 Rahima Moosa 
 
 
306 infants excluded – only birth 
weight (no follow-up) 
2621 HEU dyads ≤ 28 weeks 
310 McCord; 2311 Rahima Moosa  
Minimum 2 visits & 2 weight measures 
 
2642 HEU dyads 
Minimum 2 visits & 2 weight 
measures 
 
Baseline maternal and infant characteristics 
The median age at visits within the first 28 weeks was 2.17 months (IQR 1.48; 2.53 months). 
Majority of the infants in this analysis are from RMMCH (table 1 (a)). Overall, 83% of infants 
had a normal birth weight (>2 500g) and 51% were male. The overall median birth WAZ was 
-0.65 (IQR -1.46; 0.00); lower at RMMCH (-0.68, IQR -1.49; -0.04) compared to MH (-0.52, 
IQR -1.23; 0.31). Gestational age at delivery was only available for 70% of all infants 
(median 39 weeks, overall; IQR 37; 40). Mixed feeding was most commonly practised overall 
(78.63%), with large differences between sites; 89% and 0.65% of infants at RMMCH and 
MH were mixed fed respectively. Most infants seen at MH were formula fed (90%). Maternal 




between the two sites, with most mothers between 25–35 years old. At MH, where maternal 
regimen was recorded, 74.8% were on triple therapy (mostly non-nucleo(s)tide reverse 
transcriptase inhibitors (NNRTI) based), 18.4% on dual therapy, 0.7% NVP only and 3.6% 
did not receive ARVs. For most mothers at RMMCH who received ARVs for PMTCT, the 
regimen was not recorded (69.9%). A further 15.5% received NVP only, 0.43% triple 
therapy, 2.9% dual therapy, and 8.5% did not receive ARVs. For mothers who had antenatal 
CD4 cell count recorded, 33.6% had a CD4 cell count between 200–500 cells/µl.  
Factors affecting birth weight 
The models investigating the factors affecting birth weight are found in tables 2 (a) and (b).  
Infants with a gestational age <37 weeks had a lower birth WAZ compared to term infants (p 
<0.0001). Females had a lower birth WAZ compared to males (p=0.005), in agreement with 
previous studies [7, 12, 13, 24–26]. When looking at maternal factors, mothers who received 
ARVs, irrespective of the regimen, delivered infants with a higher birth WAZ. In comparison 
to women with a CD4 cell count >500cells/µl, those with lower CD4 cells counts delivered 
infants with a lower birth WAZ but this was only significant for mothers with a CD4 
<200cells/µl (p=0.006). Older mothers (>35 years) gave birth to infants with a significantly 
lower birth WAZ compared to mothers 25–35 years old (p=0.007).  
As a sensitivity analysis these factors (except maternal CD4 and parity where there was 
substantial missing data) were assessed for the entire HEU cohort, not limited to dyads with 
complete data on all variables, (table 2 (b)), and they remained consistent, albeit slightly 





Table 1 (a) HEU infant characteristics 
Characteristics McCord Rahima Moosa Overall 
    n 
% 
missing median/% IQR n 
% 
missing median/% IQR n median/% IQR p-value 
 
Infants (n) 310 
   
2311 
   
2621 
   
 
% male 53.9% 
   
50.6% 















  anthropometry birth  z-scores 
            
 




-0.35 -1.09; 0.31 1169 
 





-0.52 -1.47; 0.15 1142 
 
-0.75 -1.56; -0.08 1285 -0.73 -1.52; -0.07 
 
 




0.06 -0.47; 1.12 1109 
 





0.46 -0.62; 1.53 1076 
 
-0.08 -1.15; 0.99 1217 -0.08 -1.15; 0.99 
 
 




0.42 -0.36; 1.21 1099 
 





0.10 -0.74; 0.95 1079 
 
0.10 -0.74; 0.95 1218 0.10 -0.74; 0.95 
 delivery delivery variables 
            
 
gestational age (weeks) 156 49.7% 38 38; 39 1674 27.6% 39 37; 41 1830 39 37; 40 0.0411* 
 
1 min apgar 288 7.1% 8 7;8 1723 25.4% 9 9;9 2011 9 8;9 <0.0001* 
 
5 min apgar 288 7.1% 9 9;9 1689 26.9% 10 9;10 1977 10 9; 10 <0.0001* 
feeding 
Infant feeding (at birth/1st 
visit) 
           
<0.0001# 
 




















































  visits visits per patient (n=total obs) 1548   3 2;5 6600   2 1;3 8148 2 1;3 <0.0001* 













    
 
    n median IQR 
 
n median IQR 
 
n median IQR p-value 
age delivery age (years) 
 
310 29.81 25.63; 33.62 
 
2303 29.57 25.54; 33.56 
 
2613 29.61 25.57; 33.56 0.7995* 
 
age categories 
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  CD4 cells/µl CD4 cells/µl during pregnancy 
 
229 316 207; 471 
 
1330 362 240; 501 
 
1559 357 236; 500 0.0140* 
 
Categorised CD4 cell count 























































  ARVs ARV summary 
            
0.002#§ 











































   PI regimen  34 11.0%      -       34 1.3%     
 
















  IQR: inter-quartile range; ARVs: antiretroviral drugs; NVP: nevirapine; AZT: zidovudine; NNRTI: non-nucleot(s)ide reverse transcriptase inhibitors; PI: protease inhibitors *Wilcoxon rank-sum test #Chi-squared/Fisher‘s exact test §Any ARVs, no ARVs and 











unadjusted ß 95% CI p-value 
 
adjusted ß 95% CI p-value 
Term ≥ 37 weeks 0 





-0.865 -1.03; -0.700 * 
 
-0.829 -0.995; -0.663 * 
Unknown GA 
 
-0.056 -0.204; 0.092 0.461 
 
-0.028 -0.176; 0.0120 0.713 
         Any ARVs 
 
0 
   
0 
  No ARVs 
 
-0.490 -0.781; -0.199 0.001 
 
-0.387 -0.668; -0.106 0.007 
ARVs missing information 
 
-0.326 -0.876; 0.225 0.246 
 
-0.247 -0.776; 0.281 0.359 
         
25 - 35 years¶ 
 
0 
   
0 
  Young mother 
 
-0.010 -0.165; 0.144 0.895 
 
0.036 -0.123; 0.194 0.657 
Older mother 
 
-0.217 -0.378; -0.056 0.008 
 
-0.221 -0.381; -0.061 0.007 
                  Male sex 0 
   
0 
  Female sex  -0.200 -0.321; -0.079 0.001 
 
-0.164 -0.280; -0.049 0.005 
         CD4 ≥500 
 
0.000 
   
0 
  CD4 < 200 
 
-0.309 -0.497; -0.122 0.001 
 
-0.253 -0.0434; -0.072 0.006 
200 < CD4 < 500 -0.074 -0.217; 0.068 0.305 
 
-0.091 -0.228; 0.045 0.19 
         parity = 0 
 
0 
   
0 
  parity = 1 
 
0.212 0.053; 0.372 0.009 
 
0.263 0.105; 0.420 0.001 
parity ≥ 2   0.084 -0.075; 0.243 0.303   0.211 0.042; 0.381 0.015 





Table 2 (b) Linear regression weight-for-age z-scores, birth weight; n=2621 
   
unadjusted 




unadjusted ß 95% CI p-value 
 
adjusted ß 95% CI p-value 
Term ≥ 37 weeks 0 





-0.926 -1.07; -0.784 * 
 
-0.865 -1.007; -0.724 * 
Unknown GA 
 
-0.405 -0.515; -0.294 * 
 
-0.398 -0.510; -0.287 * 
         Any ARVs 
 
0 
   
0 
  No ARVs 
 
-0.492 -0.678; -0.306 * 
 
-0.375 -0.556; -0.194 * 
ARVs missing information 
 
-0.507 -0.816; -0.198 0.001 
 
-0.376 -0.677; -0.074 0.015 
         
25 - 35 years¶ 
 
0 
   
0 
  Young mother 
 
-0.025 -0.151; 0.102 0.700 
 
-0.008 -0.130; 0.114 0.902 
Older mother 
 
-0.299 -0.432; -0.166 * 
 
-0.251 -0.379; -0.122 * 
Unknown age¶ 
 
-0.978 -1.89; -0.065 0.036 
 
-0.592 -1.481; 0.296 0.191 
                  Male sex 
 
0 
   
0 
  Female sex  -0.134 -0.234; -0.033 0.009   -0.110 -0.207; -0.013 0.027 




Table 3 Longitudinal linear regression† weight-for-age z-scores 0-28 weeks 
 
Model including parity; n=2328 
 































   
0 
   
0 
   
0 
  formula 
feeding 0.362 0.156l 0.568 0.001 
 
0.841 0.349; 1.334 0.001 
 
0.310 0.156; 0.465 * 
 
0.453 0.075; 0.831 0.019 
formula 
feeding x age 0.012 0.004; 0.021 0.005 
 
-0.043 -0.069; -0.018 0.001 
 
0.014 0.008; 0.020 * 
 
-0.021 -0.039; -0.003 0.022 
unknown 
feeding -0.056 -0.382; 0.270 0.736 
 
0.196 -0.082; 0.475 0.167 
 
-0.109 -0.433; 0.214 0.508 
 
0.106 -0.163; 0.375 0.439 
unknown 
feeding  x age -0.002 -0.017; 0.012 0.761 
 
-0.026 -0.044; -0.008 0.004 
 
-0.005 -0.018; 0.009 0.491 
 
-0.025 -0.041; -0.009 0.002 
                birth weight 
≥2500g 0 
   
0 
   
0 
   
0 
  birth weight 
<2500g -2.432 -2.539; -2.326 * 
 
-2.447 -2.553; -2.341 * 
 
-2.612 -2.712; -2.512 * 
 
-2.620 -2.720; 2.520 * 
birth weight 
<2500g x age 0.068 0.059; 0.076 * 
 
0.069 0.061; 0.078 * 
 
0.067 0.060; 0.074 * 
 
0.068 0.061; 0.075 * 
                
Male sex  0 
   
0 
   
0 
   
0 
  Female sex  -0.086 -0.185; 0.013 0.088 
 
0.048 -0.029; 0.125 0.225 
 
-0.102 -0.200; -0.003 0.044 
 
0.059 -0.015; 0.134 0.119 
Female sex x 
age 0.016 0.010; 0.022 * 
 
0.013 0.007; 0.019 * 
 
0.016 0.010; 0.021 * 
 
0.012 0.007; 0.017 * 
                                age (weeks) 0.032 0.029; 0.036 * 
 
0.016 0.009; 0.023 * 
 
0.036 0.034; 0.039 * 
 
0.025 0.012; 0.038 * 
                parity = 0 0 
   
0 
   
ǂ 
   
ǂ 
  parity = 1 0.159 0.029; 0.290 0.017 
 
0.177 0.078; 0.279 0.001 
 
ǂ 
   
ǂ 
  parity = 1 x 
age -0.002 -0.010; 0.006 0.700 
 
-0.001 -0.009; 0.006 0.709 
 
ǂ 
   
ǂ 
  parity = 2 0.056 -0.075; 0.186 0.404 
 
0.174 0.072; 0.276 0.001 
 
ǂ 
   
ǂ 
  parity = 2 x 
age -0.007 -0.015; 0.001 0.085   -0.008 -0.016; -0.0002 0.045   ǂ       ǂ     





Effects on growth 
The main outcome of this analysis is longitudinal growth of HEU infants. The main model is 
presented in table 3. This model includes parity and thus excludes all dyads missing 
information on parity (11.10% overall). The second model in the table shows the magnitude 
of effects among all infants, excluding any variables with missing information. Lastly, in 
supplementary table 4, the model including maternal HIV-related variables (CD4 and ARVs) 
is shown. Dyads with missing maternal age (0.31% overall), maternal CD4 cell count 
(40.52% overall) and parity are excluded. In the reference group of HEU infants, for male 
infants of nulliparous women with a birth weight >2 500g born at RMMCH and who received 
breast milk, WAZ increased from birth through to 28 weeks of age (adjusted ß 0.016, p 
<0.0001). 
As expected, infants with a low birth weight (LBW) had a lower birth WAZ compared to 
normal birth weight infants, but over time, growth was significantly faster among LBW infants 
(adjusted ß 0.07 per week, p <0.0001). Similarly, infants born to women with parity ≥1 had a 
higher birth WAZ but experienced a slower increase in WAZ; although the latter effect was 
small (adjusted ß = -0.008) and only statistically significant for infants of mothers with parity 
≥2. In this cohort of HEU infants, females experienced faster growth (adjusted ß 0.013, p 
<0.0001) compared to male infants. 
Although FF infants (and those with missing feeding information) had a greater birth WAZ 
compared to infants who received any BF (FF infants p = 0.001, missing feeding p=0.167), 
their growth over time was slower compared to infants who had received any breast milk (FF 
infants adjusted ß -0.04 p=0.001, missing feeding adjusted ß -0.03 p=0.004).  
When looking at the model including all infants, thus not taking parity into account (table 3), 







This same analysis was conducted among infants with a birth weight ≥2 500g (as a 
sensitivity analysis) and the direction of these effects remained the same, although the 
magnitude tended to be smaller (table 5, supplementary material). A model was run 
including maternal CD4, ARVs and maternal age (supplementary material, table 4 for all 
infants and table 6 for normal-weight infants). These maternal factors did not have significant 
effects on growth over time.  
Discussion 
In this cohort of HEU infants, mothers with more advanced disease, and those not on ARVs, 
delivered infants with a lower birth weight compared to mothers with less advanced disease, 
and those who received any ARVs, whether as prophylaxis or triple ART. In contrast, in this 
cohort of mostly mixed-fed infants, no maternal HIV disease factors were associated with 
postnatal growth, with postnatal WAZ increasing in all children.  
Maternal HIV infection is associated with preterm deliveries, LBW, and small for gestational 
age (SGA) infants [27]. There is also some evidence that more severe maternal disease 
(higher viral load and low CD4) increases the odds of preterm and LBW deliveries [28]. 
Evidence is mixed for the effect of ARVs on birth weight and preterm deliveries, although 
triple ART, especially the use of protease inhibitor-containing (PI) regimens, either pre-
conception or initiated during pregnancy increases the risk of both LBW and preterm 
deliveries [27, 29].  
We found ARV use protective against LBW. In our study, relatively few women would have 
conceived on ART and very few were on PI-containing regimens. Maternal triple ART would 




exposure were combined in this analysis so the effects seen are probably due to the partial 
mitigation of the effects of severe maternal disease by ARVs. 
Most HEU infants in the IeDEA-SA collaboration were not exclusively breastfed: the 
predominant feeding modalities were MBF at RMMCH and FF at MH. FF infants 
experienced slower growth compared to MBF infants suggesting that any breast milk 
exposure has a positive impact on growth. However, the effect was very small and it is 
difficult to draw robust conclusions given the between-cohort differences in predominant 
feeding modality as well as other factors that may differ between these cohorts e.g. the 
provision of free formula changed over time and may have been different at the two sites. 
Furthermore, we did not have detailed data on other factors that are likely to impact growth, 
such as maternal education [4, 8, 16, 17] and socioeconomic status [4, 16, 17]. Goga et al 
[14] found differences between sites for the combined end-point of HIV transmission or 
death, and Ramokolo et al found differences in  growth across the same sites [30], thus the 
effect of different settings and patient characteristics within these settings are an important 
consideration. It is important to note the reality that most infants were not exclusively 
breastfed and many were FF. While this may have changed recently with the introduction of 
option B/B+ in South Africa, strategies to support breastfeeding and optimise growth 
outcomes in the context of actual infants feeding choices need to be developed and 
encouraged. 
Advanced maternal disease has been shown to negatively impact on growth [4, 16], 
although in this analysis, maternal CD4 and the use of ARVs did not have a significant 
impact on growth. This may be because maternal ARV and CD4 data were limited to the 
antenatal period and may not reflect the maternal disease status after delivery. In addition, 
the availability of triple therapy for all women with a CD4 cell count <350 cells/µl after 2010 
may have mitigated the adverse effects of severe maternal disease seen in studies prior to 




In this analysis, female infants experienced faster growth compared to male infants. 
Interestingly, previous studies examining growth among HEU infants have not examined the 
effect of infant sex [5, 8, 16]. However, Kuhn et al found that female infants had lower actual 
weight compared to male infants between 1 week and 4 months of age [4], while in a 
Ugandan study female infants had lower odds of experiencing stunting (length-for-age z-
score <-2) or being underweight (WAZ <-2) compared to male infants [17]. 
Strengths and limitations 
The major strength of this study is the large number of mother-infant dyads included and the 
description of feeding practices and growth in infants in a routine care setting. Most previous 
studies of growth in HEU infants in South Africa have been restricted to research cohorts 
and randomised controlled trial data, where results may differ compared to infants in routine 
care. However, the reliance on routinely collected data meant that a number of key variables 
were missing. For example, although only 5% of birth length and head circumference were 
missing, these were not regularly measured and recorded at follow-up visits so we were 
unable to examine length-for-age and weight-for-length z-scores over time. Furthermore, 
although standard practice was employed for growth monitoring, no quality assurance 
processes were in place. Information on ARVs given to infants themselves for PMTCT was 
inadequate thus we were unable to take it into account. Similarly, the introduction of solids 
was not routinely assessed and could not be included in the multivariate analyses. A 
previous study evaluating infant feeding practices found that 47% of HIV-infected mothers 
did not initiate breastfeeding; however, 67% of these mothers who initiated FF were 
practising mixed formula feeding by 3 weeks of age [14]. Mixed FF also comprises mixed 
feeding; as the introduction of solids was not assessed the extent of mixed FF in this cohort 
of HEU infants is unknown. Since rates of EBF are low, the effect of MBF and the 




time. Feeding modality and maternal disease severity are known to influence risk of infection 
in infants [4, 10] which would affect growth. However as opportunistic infections were not 
routinely recorded at sites, this was not investigated. 
As only antenatal maternal disease-related factors were included in this analysis, it could 
account for our finding of an impact on birth WAZ, but not longitudinal WAZ. The impact of 
postnatal maternal disease severity may have an impact on infant growth outcomes, 
particularly if infants are breastfed, as it‘s been shown that mothers who have more 
advanced disease have poorer infant outcomes [4, 5, 8, 15–17, 31–33], not merely limited to 
growth 
In our cohort of HEU infants birth WAZ was low, but whether this was as a result of HIV-
exposure or not is unknown. A comparison between HEU infants and unexposed uninfected 
infants is needed to investigate this further. Two South African studies have found that HEU 
infants have similar growth outcomes compared to unexposed infants, with one study only 
finding differences between the ages of 25-39 weeks [5, 30]. 
Conclusion 
Despite the limitations imposed by routine clinical data, this analysis shows that maternal 
ARVs and less severe maternal disease have a positive impact on birth weight. We also 
found that exclusive breastfeeding was rare in this cohort; however, any exposure to breast 
milk may have a positive effect on postnatal growth. With the introduction of option B/B+ it 
will be important to examine the impact on infant feeding pattern, infant morbidity and the 
impact on growth in the growing population of HEU infants. In addition, the effect of the early 
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1.1 General remarks 
 This document provides guidance on the preparation of data tables for the transfer of 
data for the IeDEA Southern Africa Collaboration. 
 It is requested that each clinic prepares ten separate tables with the new data, as 
described in detail below. While 6 of these tables should be submitted by all sites, 
tables 7 -10 will only be applicable to certain sites (see below).  
 The tables can be sent in the format that is most convenient for the site, including MS 
Excel, MS Access, ASCII etc. Please contact the IeDEA data manager if you have 
any queries.  
 It is appreciated that for some clinics it may be easier to send their data as they 
stand (for example in Excel) and to leave the data management and preparation 
of the tentacles to the data centre. This is not a problem, but it is requested 
that a separate document be included with a list of the variables in the dataset 
and brief descriptions/definitions.  
 It is accepted that there will be missing data for some patients, and even entire 
missing tables from some sites who simply do not have that data in electronic format.  
 It is requested that for security purposes, data tables be encrypted and compressed with WinZip 9 or 
higher using the AES encryption algorithm prior to sending.  The encryption password (minimum of 10 
characters long, including upper/lower case, numbers and special characters) should be 
communicated to the relevant data centre contact person by fax or by telephone.   
 The use of UCT’s Vula site is encouraged; this is an open-source tool allowing for the secure transfers 
of data from sites to the Data Centre.  Vula is open and accessible 24 hours a day, 7 days a week.   
 Please ensure that the dataset has been stripped of personal identifying information prior to sending. 
 Please include a unique anonymous identifier for each patient (PATIENT) for cross-reference with 
your own database. It can be the identifier you are using or a special identifier you create for IeDEA 
Southern Africa. This anonymisation key must be maintained by the site under secure conditions.  
 Sites treating children should please send the date at which they changed from using the WHO 3-
stage clinical staging system to the 4-stage clinical staging system. 
 This version of the DTF for the first time includes tables and fields specifically for the transfer of data 
on HIV exposed uninfected (HEU) children. For sites that do not collect data on these patients, the 
DTF is largely unchanged and these new tables and fields can be ignored. 
 Thank you very much for your contribution to this collaborative project! 
1.2 Inclusion criteria for patients 
Please include all patients with the following characteristics:  
 Documented HIV-1 infection  
 Patients in care at the facility for whom the date of first visit at the facility is known 
exactly. 




 Where possible, it is intended that data be transferred on HIV-infected patients 
followed-up at the facility irrespective of whether or not they received highly active 




 When transferring data just on patients who received HAART, it is preferable to 
include patients irrespective of whether or not they were exposed to antiretrovirals 
before the recorded HAART start date. In other words treatment-naïve and 
treatment-experienced patients are included. 
 Sites should send all information on all patients (adults and/or children) in a single 
dataset. For adult patients (those whose first visit at your facility was after their 
16th birthday) the paediatric specific fields (highlighted in blue) do not need to be 
completed (i.e. enter code 88 – not applicable). Paediatric specific fields must be 
entered as completely as possible for all patients whose first visit at your facility is 
before their 16th birthday even if their follow-up extends beyond the age of 16 
years.  
 Some patients will have been in care at another facility prior to commencing care at 
your facility. These patients should be included in the dataset, noting against the 
relevant field that they have been transferred in. All treatment and opportunistic 
infection (OI) history prior to commencing care at the facility should be reconstructed 
as far as possible and entered in the appropriate tables, with unknown codes for 
dates of start and end date of OIs/antiretroviral drugs where necessary. 
 HIV-exposed uninfected infants (HEU) 
o Where possible, it is intended that data be transferred on HIV-exposed 
uninfected (HEU) infants followed-up at the facility irrespective of whether or 
not their mothers‘ have undergone PMTCT or been on HAART prior to 
delivery, and irrespective of whether their mothers received PMTCT or 
HAART at the same facility. 
o The primary patient record for HEU patients will be in the PAT_HEU table. All 
patients will be entered into the patient table (PAT) and when HEU patients 
become HIV-infected they will be entered into the PAT_HIV table.  
o HEU infants who subsequently become HIV-infected will have a single unique 
anonymous identifier and single record in the PAT, PAT_HEU and PAT_HIV 
tables.  In this way, the infants full history from birth can be recorded by 
linking the LAB, ART, VIS, OI and other tables to the single patient record in 
the PAT_HEU, PAT_HIV and PAT tables from birth until the time of HIV 
diagnosis, and from there until start of ART if infant/child starts treatment. 
o Ideally, data from HEU infants and their mothers should be linked as mother-
infant pairs using the LINK table. In other words, the mother will have a record 
in the PAT and PAT_HIV tables and the infant a record in the PAT_HEU table 
and these will be linkable via the LINK table. Details of the pregnancy will be 
recorded using the mother‘s identifier in the PREGNANCY table. The 
PREGNANCY table will also include the infant‘s unique identifier. Infant birth 
details are recorded in a separate table, INFANT table and this includes both 
the mother and infant‘s unique identifiers if they were both treated at the 
same site. 
o HEU infants not identified at birth or soon after, but during admission or 
hospital consultation for illness may also be included. Unless the mother is a 
patient at the facility, it is not necessary to include a record for the mother in 
this case. The mother‘s history is unlikely to be known but her exposure to 
ART, details about gestational age and birth history of the child, and the 




appropriate tables PAT_HEU, ART, PAR_HEALTH and PREGNANCY tables 
specifically).  
1.3 Dates 
 The term baseline will not be used as this creates confusion. We will rather make use 






Variable name Definition of key date 
FRSVIS_DMY Date of first visit at your facility 
HIVP_DMY  
(HIVP_Y (year) and HIVP_M (month) if exact 
date unknown) 
Date of first positive HIV-1 test 
HAART_DMY Date of HAART initiation 
 
 For all fields that require a date, the precise date should be entered in the format  
dd-mm-yyyy if it is known. If the precise date is not known, the month and year 
should be entered separately as far as possible in the separate dedicated fields 
provided for these, and the precise date field should be left blank.  
 If month or both the year and month are unknown, the precise date field should be 
left blank and unknown codes should be entered into the year field (9999) and the 
month field (99) as appropriate.   
 For certain date fields a precise date is obligatory e.g. date of first visit at your facility 
(FRSVIS_DMY) and date of HAART initiation (HAART_DMY). In patients who 
commenced HAART at another facility, if the precise date of start of HAART cannot 
be estimated reasonably accurately, the patient should be entered as treatment 
experienced and the date of first visit at your facility will be regarded as the date of 
start of HAART. 
1.4 Definitions 
 HAART is defined as treatment with a combination of at least three drugs from any 
class or classes.  
 ―Treatment experienced‖ is defined as previous exposure to any antiretroviral drug 
for at least 30 days, excluding exposure for prevention of mother to child 
transmission (PMTCT) or post-exposure prophylaxis (PEP). 
 HEU infants/children are exposed to HIV in utero and/or perinatally or through 
breastfeeding but are not known to be infected at their first recorded visit at the 
facility (usually at birth or soon thereafter).   
 
1.5 Standard codes 
Certain codes will appear repeatedly in a number of lists for coded fields. In this 
instance, the same codes/coding format will be used in all fields where these codes 










95 Not ascertained/Not collected at this facility 
99 Unknown despite attempting ascertainment  
88 Not applicable 
1.6 Data tables 
For each clinic, the following five to ten data tables or files should be prepared, depending 
on data availability.  
 A minimum of two tables are required by all sites. Table 1.1 and either Table 1.2 or 
Table 1.3 or all three are required by all sites. Table 1.1. (PAT) is required for all 
patients at their first visit. Table 1.2. (PAT_HIV) is required for HIV-infected patients, 
with a known infection at their first visit. Table 1.3 is required for HIV-exposed infants 
who are not known to be infected at their first visit. HEU who subsequently become 
infected will have a record in PAT, PAT_HEU and PAT_HIV tables with the same 
anonymous patient identifier. 
 Tables 2 to 5.1 are required by all sites. If sites are collecting information on HEU 
patients, table 5.2 is also required.  
 Table 6 (LINKAGE DATA) is required only for sites that record information on families 
o For mother-child pairs for HEU infants this is required 
 Table 7 (PREGNANCY) is required only for sites that record information on 
pregnancy electronically.  
o Where possible, if a female patient with documented HIV-1 infection is 
followed up at a facility and becomes pregnant with or without ARV initiation 
this table should be completed. For HEU infants, it is particularly important to 
provide as complete data as possible on the mother‘s pregnancy using this 
table. 
o If the pregnancy outcome is a live birth, table 8 (INFANT) needs to be 
completed as well. 
 Table 8 (INFANT) is used to record the birth information of a child (both HEU and 
infected). The birth information includes birth anthropometry, agpars and mode of 
delivery. 
 Table 9 (PAR HEALTH) is required only for patients who commence care before their 
16thbirthday.  
o Where possible, this should be completed and updated at each visit as 
appropriate for HEU infants. 
 Table 10 (TB) is required only from sites that record detailed information on episodes 
of tuberculosis electronically.  
 Table 11 (TRIAL) is required only for sites where patients may be enrolled on clinical 
trials or research studies apart from cohort analyses of routinely collected data.  
 In addition, a table summarising with information on the overall cohort or ―meta-data‖ 
for the transfer, should be included with all transfers. 
 
1.  1.1 PAT (Patient data): A table containing socio-demographic data on patients, as 




patient. In other words, each patient will appear only once in this table. We propose 
that this table is called PAT.  
1.2 PAT_HIV (Patient data for HIV-infected patients): A separate table containing 
patient characteristics at start of HAART in HAART treated patients. We propose that 
this table be called PAT_HIV. 
1.3PAT_HEU (Patient data for HEU infants):  A separate patient table containing 
similar information to the PAT_HIV table will be used for exposed uninfected infants. 
We propose that this table is called PAT_HEU. 
1. LAB (Laboratory data at baseline and follow-up): This is a single table containing 
all laboratory data: CD4, HIV viral load, and all other laboratory tests, including HIV 
diagnostic tests in the case of HEU infants.  One line will correspond to one 
laboratory result. In other words, most patients will have multiple records in this table. 
We propose that this table is called LAB. 
2. ART (Antiretroviral treatments): A table with the data on all antiretroviral drugs that 
a patient has received or been exposed to including PMTCT (both exposure to 
mother as well as infant peri- or post-natal) or post-exposure prophylaxis. This 
includes treatment received at your facility and at other facilities.  The table will 
contain one line for each separate drug, with different fields for the drug name (code), 
the prescription start dates and stop dates.  Most patients will have numerous 
records in this table.  The drug history of patients who commence care at your facility 
but have previously been treated at another facility should be reconstructed and 
entered into this table as far as possible. We propose that this table be called ART. 
3. OI (Opportunistic Events): A table with the information on all opportunistic 
infections or incident HIV-associated diagnoses. One line will correspond to one 
clinical event with different fields for the event type (code), the start dates and stop 
dates. It is anticipated that stop dates will often not be known. In other words, some 
patients will have more than one record in this table and some may have no records 
in this table. History of opportunistic events occurring prior to commencing care at 
your facility should be reconstructed as far as possible. For HEU infants, clinical 
illnesses (e.g. respiratory tract infections, gastro-enteritis) will be recorded using this 
table and the associated OI codes, although HIV staging will not be relevant. We 
propose that this table be called OI. 
4. 5.1 VIS (Visit data): A table containing information on all clinical visits (including the 
first visit at your facility). One line will correspond to one visit.  Most patients will have 
more than one record in this table. Note that a number of fields in this table only need 
to be completed for HEU infants, denoted by the prefix HEU_ and highlighted in 
orange. We propose that this table be called VIS. 
5.2 VIS_HEU A table containing additional information from all clinical visits particular 
to HEU patients. One line will correspond to one visit. For HEU patients both table 
5.1 and 5.2 need to be completed as far as possible. 
5. LINK (Linkage data): A table containing information on family members (partners, 
children and siblings) also receiving HIV care either within your cohort or at another 
site. All family members receiving HIV care should be included whether they are 
receiving care at an IeDEA collaborative site or at a non-IeDEA site. One line will 
correspond to one family member receiving HIV care. In other words, some patients 
will have more than one record in this table and some may have no records in this 
table. The data in this table will be used to link HEU infants with their mothers to 
generate a database of mother-infant pairs.  We propose that this table is called 
LINK. 
6. PREGNANCY (Pregnancy data): A table containing information on all pregnancies, 




outcomes. One line will correspond to one pregnancy. Multiple pregnancies will each 
have a record in the table, with the outcome of the relevant foetus recorded. Some 
patients will have more than one record in this table, while others (including all males 
and children less than 10 years) will have no records in this table. For mothers of 
HEU infants, this table should be filled in as completely as possible to capture data 
regarding the mothers‘ pregnancy history if the mother is a patient at your facility. 
The infant‘s unique identifier will also be included in this table. We propose that this 
table be called PREGNANCY. 
7. INFANT (Infant birth data): A table containing birth information on infants (HEU and 
HIV-infected). This will include birth anthropometry. This table is specifically needed 
for HEU infants. The mother‘s unique identifier will be included in this table. We 
propose that this table be called INFANT. 
8. PAR_HEALTH (Parental health): A table with information on parental health status. 
This table is only required for sites sending data on patients 15 years old and 
younger at their first visit to the facility.  This table is linked to the visit table, so ideally 
there is an update on parental health status at every visit (especially for HEU 
patients). Alternatively, this table should be filled in at least once, either for the first 
visit at your facility or the date of start of HAART.  
9. TUBERCULOSIS (Tuberculosis data): A table with information on all episodes of 
tuberculosis (TB). This table is only for sites that record detailed information on TB 
episodes. Sites that do not collect detailed information on TB episodes should enter 
the TB episodes in the OI table. One line will correspond to one TB episode. In other 
words, some patients will have more than one record in this table and some may 
have no records in this table. We propose that this table be called TB. 
10. TRIAL (Enrolment in trials): A table with information on any trial or research study 
(apart from cohort analysis of routinely collected data) on which a patient is enrolled.  
This table is only for sites running trials or research studies. One line will correspond 
to one trial/research study on which the patient is enrolled. In other words, some 
patients will have more than one record in this table and some may have no records 
in this table. We propose that this table be called TRIAL. 
11. OUTCOME_REVISED: (Death registry linkage data) A table with information on 
updated death status following linkage to registry systems. 
12. MET (Meta-data):  A table comprising key characteristics of the data that is 
transferred. 
 
2 Variables to be included in core tables 
2.1 Socio-demographic characteristics and outcomes (PAT & PAT_HIV & PAT_HEU 
tables) 
Table 1 below details the data that should be included in PAT table.  
The patient identification variable (PATIENT) must be unique, and it cannot be missing in 
any of the tables. This field must contain a unique and anonymous patient identifier; the field 
must NOT contain their name or any other identifying information. It is up to the local 





Table 1.1 – Variables to be included in PAT table 
Name Format and definitions Description 
MERGE Numeric Number of merge 
PATIENT Free (numerical or alphanumerical) Unique, anonymous, patient identifier 
COHORT Text Text field identifying the cohort 
FACILITY Text Text field identifying particular clinic 
within cohort, if more than facility 
within the cohort 
BIRTH_DMY DATE (dd-mm-yyyy) Date of birth  
Enter exact date in this field if known. 
 If unknown leave blank and enter 
month and year as far as possible in 
fields below. 
BIRTH_Y Numeric (for example 1960) 
9995 = Not ascertained 
9999 = Unknown despite attempting 
ascertainment 
Year of birth 
BIRTH_M Numeric (for example 8) 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Month of birth 
GENDER Numeric with codes: 
1 = Male 
2 = Female 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Sex / gender of patient 
FRSVIS_DMY DATE (dd-mm-yyyy) Date of first visit at facility 
(Note: This date must be entered 
exactly) 
ENTRY Numeric with codes (see List 1) Mode of entry to your facility 
ENTRY_OTHER Text Details of other mode of entry not 
listed in List 1 
MTCT_Y Numeric with codes: 
0 = No (No MTCT exposure ) 
1 = Yes (MTCT exposed, drug history 
reconstructed  and recorded in ART 
table) 
2 = Yes (MTCT exposed, drug history 
not reconstructable)   
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Patient exposed to MTCT drugs 
(either mother during pregnancy or 
infant peri- or post-natally) prior to 
start of HAART (HAART_DMY)? 
This should be entered for all 




DATE (dd-mm-yyyy) Date of last contact 
Note: This date must be entered 
exactly. 
LAST_CONTACT_T Numeric with codes (See List 4) Type of last contact 
OUTCOME Numeric with codes (See List 5) Outcome including death and loss to 
follow-up 
OUTCOME_DMY DATE (dd-mm-yyyy) Date of outcome  
(Leave blank if outcome is Alive [in 
care] or  
Alive [not in care]) 
OUTCOME_Y Numeric (e.g. 2004) 
8888 = Not applicable or exact date 
of outcome entered above 
9995 = Not ascertained  
9999 = Unknown despite attempting 
Year of outcome 
Enter 8888 for patients who have 





Name Format and definitions Description 
ascertainment 
OUTCOME_M Numeric (e.g.12) 
88 = Not applicable or exact date of 
outcome entered above 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Enter 8888 for patients who have 
not died, or if exact date of outcome 
entered above. 
Month of outcome 
Enter 88 for patients who have not 
died, or if exact date of outcome 
entered above. 
DEATH_C1 Numeric with codes (see List 6) Cause of death : 
Enter 88 for patients who have not 
died 
DEATH_N1 Text with following codes: 
I = Immediate cause 
U = Underlying cause/condition 
C = Contributing cause 
N = Not available 
Note : There are 3 fields for 3 
causes of death to be entered in no 
specific order. If an HIV-related 
cause of death is recorded, please 
ensure that the condition is recorded 
appropriately in the OI table.   
Nature of contribution of cause: 
For each cause of death, please 
characterise the contribution of the 
specific cause. 
DEATH_C2 Numeric with codes (see List 6) For each cause of death, please 
characterise the contribution of the 
specific cause. 
DEATH_N2 Text with following codes: 
I = Immediate cause 
U = Underlying cause/condition 
C = Contributing cause 
N = Not available 
For each cause of death, please 
characterise the contribution of the 
specific cause. 
DEATH_C3 Numeric with codes (see List 6) For each cause of death, please 
characterise the contribution of the 
specific cause. 
DEATH_N3 Text with following codes: 
I = Immediate cause 
U = Underlying cause/condition 
C = Contributing cause 
N = Not available 
For each cause of death, please 
characterise the contribution of the 
specific cause. 
DEATH_TXT Text  
BRSTFD Numeric with codes 
10 = breastfed, exclusive 
11 = breastfed, exclusivity unknown  
12 = mixed fed (breastfed & formula 
fed) 
20 = Formula fed (never breastfed) 
30 = HEU, feeding information 
entered in visits table 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown, despite attempting 
ascertainment 
Infant feeding history  (0-6 months of 
age) for infants older than 6 months 
at first visit. 
 
For HEU infants, please enter 
feeding information into the visits 
table (table 5.2)  
 
(paediatric patients only - enter 88 
for adult patients) 
BRSTFD_ED DATE (dd-mm-yy) Date of cessation of breast feeding if 
applicable 
Leave blank if not applicable, child 
still being breastfed, date not known, 
or child not breastfed at all. 
BRSTFD_EST_DUR Numeric (e.g. 2) Estimated duration of breastfeeding 




Name Format and definitions Description 
exclusively breastfed or mixed fed. 
 
 
Table 1.2 – Variables to be included in PAT_HIV table 
Name Format and definitions Description 
PATIENT Free (numerical or alphanumerical) Patient identifier from PAT table 
MODE Text with codes (see List 2) Most probable mode of  HIV 
transmission 
HIV_TYPE Numeric with codes (for example 1) 
1 = HIV-1 
2 = HIV-2 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Field to distinguish HIV-1 from HIV-2 
HIVP_DMY DATE (dd-mm-yyyy) Date of first positive HIV test 
Enter exact date in this field if known. 
 If unknown leave blank and enter 
month and year as far as possible in 
fields below. 
HIVP_Y Numeric (for example 2001) 
9995 = Not ascertained 
9999 = Unknown despite attempting 
ascertainment 
Year of first positive HIV-1 test 
HIVP_M Numeric (for example 8) 
95 = Not ascertained  
99 = Unknown despite attempting 
ascertainment 
Month of first positive HIV-1 test 
HIV_TEST Numeric with codes (IeDEA SA codes) 
1 = Presumptive diagnosis 
2 = Serology 
3 = PCR 
4 = P24 
5 = Rapid test 
90 = Other 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Type of test used for diagnosis 
HAART Numeric 
0 =  Never started HAART 
1 =  Started HAART 
Conditional: 
If 1 then go to HAART_DMY 
HAART_DMY DATE (dd-mm-yyyy) Date of HAART initiation  
(minimum 3 drugs together) 
Note: This date must be entered 
exactly. If patient commenced HAART 
at another facility and the exact date is 
not known, the patient should be 
entered as ―Treatment experienced‖ in 
the EXP_Y field below and the first 
visit 
at your facility will be used as the start 
of HAART date. 
FHV_STAGE_WH
O 
Numeric with codes: 
1 = Stage I 
2 = Stage II 
3 = Stage III 
4 = Stage IV 
Clinical WHO stage (I to IV) at time of 
starting HAART 





Name Format and definitions Description 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
FHV_SDI_1 Text (for example PCP - see List 3) 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Stage defining illness-1 at time of 
starting HAART. 
(Enter 88 patients who have not 
commenced HAART) 
Note: At least FHV_S_SDI_1 should 
be completed in patients commencing 
HAART; A maximum of 4 stage 
defining illness can be entered in the 
4 fields provided. There is no specific 
ordering to the entering of stage 
defining illnesses. 
FHV_SDI_2 Text (for example PCP - see List 3) 
0 = No further stage defining illness 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Stage defining illness-2 at time of 
starting HAART. 
(Enter 88 patients who have not 
commenced HAART) 
FHV_SDI_3 Text (for example PCP - see List 3)  
0 = No further stage defining illness 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Stage defining illness-3 at time of 
starting HAART. 
(Enter 88 patients who have not 
commenced HAART) 
FHV_SDI_4 Text (for example PCP - see List 3)  
0 = No further stage defining illness 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Stage defining illness-4 at time of 
starting HAART. 
(Enter 88 patients who have not 
commenced HAART) 
EXP_Y Numeric with codes: 
0 = No (No previous ARV experience ) 
1 = Yes (Treatment experienced, drug 
history known and recorded in ART 
table) 
2 = Yes (Treatment experienced, drug 
history not known)  
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Patient is treatment experienced prior 
to starting HAART (HAART_DMY) ?   
Experienced = Any ARV drug for at 
least 30 days before starting HAART 
(PMTCT regimen and PEP excluded)  
This should be entered for all patients 
even those who have not commenced 
HAART. 
PEP_Y Numeric with codes: 
0 = No (No PEP exposure) 
1 = Yes (PEP exposed, drug history 
reconstructed  and recorded in ART 
table) 
2 =Yes (PEP exposed, drug history not 
reconstructable)   
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Patient exposed to post-exposure 
prophylaxis (PEP) drugs prior to start 
of HAART (HAART_DMY)? 
This should be entered for all patients 
even those who have not commenced 
HAART. 
TB_FHV Numeric with codes 
0 = No 
1 = Yes 
88 = Not applicable 
95 = Not ascertained 
Patient was on treatment for TB at 
start of HAART (HAART_DMY) 





Name Format and definitions Description 
99 = Unknown despite attempting 
ascertainment 
WKS_TB_FHV Numeric (for example 8) Duration in weeks since start of TB 
treatment when HAART was 
commenced in  patients with TB at 
start of HAART 
PREG_FHV Numeric with codes  
0 = No 
1 = Yes 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Pregnant at start of HAART 
(Enter 88 for men and children <10 
years old AND all patients who have 
not commenced HAART) 
CAREG Numeric with codes (see List 7) Primary caregiver at start of HAART 
(HAART_DMY) 
(paediatric patients only – enter 88 for 
adult patients) 
DISCL_CG Numeric with codes (see List 8) Person informed of the HIV status of 
the child 
(paediatric patients only – enter 88 for 
adult patients) 
DISCL_CHILD Numeric with codes 
0 = No 
1 = Yes 
2 = In process 
88 = Not applicable (adult patient) 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Was the child informed of his/her 
status at HAART_DMY? 
(paediatric patients only - enter 88 for 
adult patients) 
 
Table 1.3 – Variables to be included in PAT_HEU table 
Name Format and definitions Description 
PATIENT Free (numerical or alphanumerical) Patient identifier from PAT table 
CAREG Numeric with codes (see List 7) Primary caregiver at first visit 
(paediatric patients only – enter 88 for adult 
patients) 
PREG_HIV 0 = Negative 
1 = Positive (time unknown) 
1.1 = Positive prior to this pregnancy 
1.2 = Positive during pregnancy (but 
before delivery) 
1.3 Positive at delivery 
1.4 Positive after delivery 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
HIV status of infant‘s mother during pregnancy 
This information is required especially for HEU 
infants whose mothers do not have their own PAT 
record in the patient table with pregnancy 
information recorded in the PREG table 
 
List 1 - Codes for mode of entry (ENTRY) 
Code source: IeDEA SA codes 
Table name: LU :PAT :ENTRY 
Codes Mode of entry 
1 PMTCT program 




Codes Mode of entry 
3 Diagnosis testing during consultation 
4 Orphans programs 
5 Family diagnosis 
6 TB program 
7 General HIV service clinic 
8 Self-referral with known diagnosis 
90 Other 
95  Not ascertained 
99 Unknown despite attempting ascertainment 
 
List 2 - Codes for mode of infection (MODE) 
Code source: Based on HICDEP codes; new codes denoted by * 
Table name: LU_mode 
Codes Mode of infection 
1 Homo/bisexual man  
2 Injecting drug user 
3 Homo/bisexual man + injecting drug user (1 + 2) 
4 Haemophiliac 
5 Transfusion, non-haemophilia related 
6 Heterosexual contact 
6.1 Presumed heterosexual 
7 Heterosexual contact + Injecting drug user (6 + 2) 
8 Perinatal 
90 Other 
95*  Not ascertained 
99 Unknown despite attempting ascertainment 
 
 
List 3 - Disease codes for FHV_SDI (PAT table) and OI_ID (OI table) 
Code source: Based on HICDEP codes; new codes denoted by * 
Table name: LU:DIS 
Note that this is a common list of HIV-associated conditions for capturing incident opportunistic infections and 
HIV-associated conditions, as well as stage-defining conditions in adults and children.  Where duration or 
recurrence is required for a condition to be stage defining, the event columns have a zero to exclude them from 
lookups of incident conditions. Where conditions are not stage defining, the stage-defining columns for children 
and adults have zeros to exclude them from lookups of stage-defining conditions. 














ANGC* Angular cheilitis 2 2 1 1 1 1 
BCGD BCG disease – disseminated 4 4 1 1 1 1 
BCGL* BCG Lymphadenitis (localised to R 
axilla) 
88 88 1 1 0 0 
BCGP* BCG Pulmonary 88 88 1 1 0 0 
BCIR* Recurrent severe presumed bacterial 
infection (excluding pneumonia)  
4 4 0 0 1 1 




single episode (excluding pneumonia) 
BCNE Bacterial pneumonia, recurrent (>2 
episodes within 1 year) 
4 3 0 0 1 1 
BCNS* Severe presumed bacterial pneumonia 
(single episode) 
88 88 1 1 0 0 
BLD* Unexplained anaemia (<8g/dl), and or 
neutropaenia (<500/mm3 – 2; 
<1000/mm3 - children), and or 
thrombocytopaenia (<50000/mm3) > 1 
month 
3 3 0 0 1 1 
CANM* Candidiasis (oral) (outside neonatal 
period)  
3 3 1 1 1 1 
CANO Candidiasis oesophogeal 4 4 1 1 1 1 
CANT* Candidiasis (trachea, bronchi or lungs) 4 4 1 1 1 1 
CLD* Chronic HIV-associated lung disease 88 3 0 1 0 1 
CMO* HIV-associated cardiomyopathy 88 4 1 1 0 1 
CMVO Cytomegalovirus other location (site 
other than liver, spleen or lymph 
nodes) (onset at age>1month) 
4 4 1 1 1 1 
CMVR Cytomegalovirus (CMV) chorioretinitis 
(onset at age>1month) 
4 4 1 1 1 1 
CRCO Cryptococcosisextrapulmonary 4 4 1 1 1 1 
CRSP Cryptosporidiosis (duration > 1 month) 4 4 0 0 1 1 
CRSPS* Cryptosporidiosis ? 88 88 1 1 0 0 
CRVC Cervical cancer (invasive) 4 88 1 1 1 0 
DEM AIDS dementia complex 4 88 1 0 1 0 
DIAC* Unexplained chronic diarrhoea (> 
1month for adults; >14 days for 
children) 
3 3 0 0 1 1 
DIAS Diarrhoea (duration <1 month - adults; 
<14 days - children) 
88 88 1 1 0 0 
ENC* HIV encephalopathy 4 4 1 1 1 1 
FBLS Focal brain lesion 88 88 1 1 0 0 
FEVC* Unexplained persistent fever (> 1 
month) 
3 3 0 0 1 1 
FNID* Fungal nail infections (fingers or toes) 88 2 0 1 0 1 
FNIF* Fungal nail infections of fingers 2 88 1 0 1 0 
HERP Herpes simplex virus ulcers (duration > 
1 month)  
4 4 0 0 1 1 
HERPS* Herpes simplex virus ulcers 88 88 1 1 0 0 














HERPV* Visceral herpes simplex infection 4 4 1 1 1 1 
HG Hodgkins Lymphoma 88 88 1 1 0 0 
HIST Histoplasmosisextrapulm. 4 4 1 1 1 1 
HPVE* Extensive human papilloma virus 
infection  
88 2 1 1 0 1 
HSM* Hepatosplenomegaly 88 2 0 0 0 1 
HZ* Herpes zoster (not specified) 88 88 1 1 1 1 
HZM* Herpes zoster (more than one 
dermatome) 




HZS* Herpes zoster (single dermatome)  2 2 1 1 1 1 
ISDI Isosporiasis diarrhoea (duration > 1 
month) 
4 4 0 0 1 1 
ISDS* Isosporiasis diarrhoea 88 88 1 1 0 0 
KS Kaposi Sarcoma 4 4 1 1 1 1 
LEIS Leishmaniasis visceral 4 88 1 1 1 0 
LEU Progressive multifocal 
leucoencephalopathy 
4 4 1 1 1 1 
LGE* Lineal gingival erythema 88 2 1 1 0 1 
LIP* Lymphoid interstitial pneumonitis 88 3 0 1 0 1 
MC Mycobacterium avium complex (MAC) 
or Kanasiiextrapulm. 
4 4 1 1 1 1 
MCDI Microsporidosis diarrhoea (duration > 1 
month) 
4 4 0 0 1 1 
MCDS* Microsporidosis diarrhoea 88 88 1 1 0 0 
MCI* Mycobacterium Immune reconstitution 
syndrome 
88 88 1 1 0 0 
MCP Mycobacterium tuberculosis pulmonary 3 3 1 1 1 1 
MCPO Mycobacterium pulmonary other 
(excluding BCG in children) 
88 88 1 1 0 0 
MCX Mycobacterium tuberculosis 
extrapulmonary 
4 4 1 1 1 1 
MCXO Mycobacterium extrapulm. other 
(excluding BCG in children) 
4 4 1 1 1 1 
MNUM* Moderate unexplained malnutrition (60-
80% EWFA) 
88 3 0 1 0 1 
MNUS* Unexplained severe wasting or 
malnutrition (<60% EWFA) 
88 4 0 1 0 1 
MOLC* Extensive molluscumcontagiosum 88 2 1 1 0 1 
MYCD* Any disseminated mycosis 4 4 1 1 1 1 
NHG Non-Hodgkin Lymphoma, not specified 88 88 1 1 0 0 
NHGB Non-Hodgkin Lymphoma, Burkitt 
(classical or atypical) 
88 88 1 1 0 0 
NHGI Non-Hodgkin Lymphoma, diffuse large 
B-cell lymphoma (immunoblasti or 
centroblastic) 
4 4 1 1 1 1 
NHGP Non-Hodgkin Lymphoma primary brain 
lymphoma 
4 4 1 1 1 1 
NHGU Non-Hodgkin Lymphoma 
unknown/other histology 
88 88 1 1 0 0 
NPO* HIV-associated nephropathy 88 4 1 1 0 1 
NUS* Acute necrotising ulcerative stomatitis, 
gingivitis or periodontitis 
3 3 1 1 1 1 
OHLP* Oral hairy leukoplakia 3 3 1 1 1 1 
ORUL* Recurrent oral ulcerations 2 2 0 0 1 1 
PARE* Parotid enlargement 88 2 1 1 0 1 
PCP Pneumocystis carinii pneumonia  4 4 1 1 1 1 
PGL* Persistent Generalized 
Lymphadenopathy 
1 1 0 0 1 1 
PPE* Papular pruritic eruptions 2 2 1 1 1 1 
RTIL* Lower respiratory tract infection (other 
than presumed pneumonia) ? 
88 88 1 1 0 0 








(Adult) (Paed) (Adult) (Paed) 
RTIR* Recurrent or chronic respiratory tract 
infection (RTIs, sinusitis, bronchitis, 
otitis media, otorrhea, pharyngitis) 
2 2 0 0 1 1 
RTIU* Upper respiratory tract infection 88 88 1 1 0 0 
RVF* Acquired HIV-associated recto-vaginal 
fistula 
88 4 1 1 0 1 
SAME Salmonella bacteraemia (non-typhoid) 
(single episode) 
88 88 1 1 0 0 
SAM Salmonella bacteraemia (non-typhoid) 
recurrent 
4 88 0 0 1 0 
SEBD* Seborrheic dermatitis 2 2 1 1 1 1 
TOX Toxoplasmosis brain (outside neonatal 
period) 
4 4 1 1 1 1 
WAST HIV Wasting Syndrome 4 88 1 0 1 0 
WTLM* Moderate unexplained weight loss 
(<10% of body weight) 
2 88 1 0 1 0 
WTLS* Severe unexplained weight loss (>10% 
of body weight) 
3 88 1 0 1 0 
 
List 4 - Codes for last contact (LAST_CONTACT_T) 
Code source: IeDEA SA codes 
Table name: LU :PAT :LAST_CONTACT_T 
Codes Last contact type 
1 Visit in the facility 
2 Phone call 
3 Home visit 
4 Hospitalisation 
5 Drug pick-up only 
6 Visit in another facility 
7 Laboratory test received 
90 Other 
95  Not ascertained 
99 Unknown despite attempting ascertainment 
 
List 5 - Codes for outcome (OUTCOME) 
 Code source: IeDEA SA codes 
Table name: LU: PAT: OUTCOME 
Codes Mode of Outcome 
10 Death (HIV-related) 
11 Death (HIV relationship unknown) 
12 Death (not HIV-related) 
20 Alive and in care at your facility 
21 Known to be alive and in care at another facility  
22 Known to be alive and patient is not in care  
23 Known to be alive but not known whether patient is in care 
30 Transfer out within the same service, vital status after transfer out unknown 
31 Transfer out to a different service, vital status after transfer out unknown 
40 Loss to follow-up despite active tracing attempted 





95 Not ascertained 
List 6 - Codes for cause of death (DEATH_C1 – 3) 
Code source: HICDEP codes; new codes denoted by * 
Table name: LU: PAT: DEATH_C 
For HIV-related and Aids defining events (8.*), it is expected that the associated event will be 
recorded in the OI table. 
Codes  Cause of Death  
1  Myocardial Infarction  
2  Stroke  
3  Other cardiovascular diseases  
4  Symptoms caused by mitochondrial toxicity  
4.1  Lactic acidosis  
5  Complications due to diabetes mellitus  
6  Pancreatitis  
7  Complications due to hepatitis  
7.1  Hepatitis related  
7.2  Liver failure not related to hepatitis or mitochondrial toxicity  
8  HIV-related  
8.1  AIDS defining event  
8.2  Invasive bacterial infection  
9  Renal failure  
10  Bleeding (haemophilia) 
20  Non AIDS defining cancer  
88* Not applicable 
90  Other  
91  Suicide 
92  Drug Overdose  
93 Accident 
95* Not ascertained 
99 Unknown, Fatal case with no information 
 
List 7 - Codes for primary caregiver (CAREG) 
Code source: IeDEA SA codes 
Table name: LU :PAT :CAREG 








88 Not applicable 
95  Not ascertained 






List 8 - Codes for person informed of the HIV status of the child (DISCL_CG) 
Code source: IeDEA SA codes 
Table name: LU: PAT: DISCL_CG 
Codes Disclosure to caregiver 
1 Mother 
2 Father 
12 Both parents 
3 Grandmother 
4 Other primary caregiver 
90 Other 
88 Not applicable  
95 Not ascertained 
99 Unknown despite attempting ascertainment 
 
2.2 Laboratory data (LAB table) 
Table 2 details the laboratory data that should be included in the LAB table.  All available 
data from the date of first visit should be included.   
Notes: 
 Results of laboratory tests must be provided in the units specified 
 Results of laboratory tests can be entered in one of two fields – a numeric field 
(LAB_V) and a coded text field (LAB_T) (for very high and/or undetectable viral 
loads, and for TB microscopy and culture results). 
 TB microscopy and culture results should only be entered in the coded result field 
(LAB_T) as follows, and not in the numeric field (LAB_V): 
 For viral loads, there is an additional field to indicate the lower limit of detection of the 
assay used. This field should be empty for other laboratory results.  
 For TB sensitivity results, there are 2 additional fields. The first (TB_DRUG) where 
the drug to which sensitivity testing has been done is entered, and the second 
(SENS), where the sensitivity is recorded using the standard yes/no format. These 
fields should be empty for other laboratory results.  
 Both CD4 percentage and absolute count should be included on paediatric patients 
until they are 16 years old. 
 There is no code for unknown values of for laboratory test results as tests of which 
the result is unknown should not be included in the dataset.  
 Only dates in the DMY format are permissible in this table 
 
Table 2 – Variables to be included in the table LAB 
Name Format and definitions Description 
MERGE Numeric Number of merge 
PATIENT Free (numerical or alphanumerical) Unique, anonymous, patient identifier 
COHORT Text Text field identifying the cohort 
LAB_DMY Date (for example dd/mm/yy) Date when specimen was taken 
LAB_ID Text (see List 9) Code representing the measurement 
LAB_V Numeric (for example 44) Numeric value of measurement 





Name Format and definitions Description 
UNIT_TXT Text ?UCT 
LAB_VSRES Numeric with codes: 
0 = Negative 
1 = Posive 
88 = Not applicable 
99 = Unknown 
results for viro-/serological tests 
LAB_T Text  
Lower than limit of detection for viral loads 
should be entered as ―LDL‖ 
TB microscopy and culture results should 








 eg. ―> 6 000 000‖ or ―P+++‖ 
Leave blank if result entered as number 
(LAB_V) 
RNA_L Numeric Lower limit of detection of RNA assay 
TB_DRUG Text with codes: 
INH_L = Isoniazid low dose 
INH_H = Isoniazid high dose 
INH_U = Isoniazid – dose unspecified 
PZA = Pyrazinamide 
RIF = Rifampicin 
ETN = Ethionamide 
ETB = Ethambutol 
STREP = Streptomycin 
QUI = Quinolone 
88 = Not applicable 
TB Drug against which sensitivity has 
been tested.  
(Enter 88 for laboratory tests other than 
viral load) 
DRUG_RES Numeric with codes: 
0 = No (Sensitive) 
1 = Yes (Resistant) 
88 = Not applicable 
Is Mycobacterium TB cultured 
RESISTANT to drug in TB-DRUG field? 




List 9: Codes for measurement type (LAB_ID) 
Code source: HICDEP codes; new codes denoted by * 
Table name: LU :LAB :LAB_ID 
Codes Measurement 
ALB Albumin (g/L) 
ALT Alanine-Aminotransferase (UI/L) 
AST Aspartate aminotransferase (UI/L) 
CD4A* CD4 absolute cell count (cells/μl) 
CD4P* CD4 percentage (%) 
CHOL Cholesterol (mmol/L) 
CRE Creatinine (μmol/L) 
HAEM Haemoglobin (g/dl) 
LACT Lactate (mmol/L) 
LYMP Total lymphocyte count (cells/µl) 
NEUT Neutrophil count (x1000/mm3) 
PLT Platelets (cells/μl) 




TBC* TB culture 
TBM* TB microscopy 
TBS* TB sensitivity 
TG Triglycerides (mmol/L) 
URE Urea (mmol/L) 
WBC White cell count (x1000/ mm3) 
PCR* HIV PCR 
P24* P24 antigen 
SER* HIV serology (ELISA) 
RAP* HIV rapid test 
HIV_UNK* Unknown HIV test type but result available 
 
2.3 Antiretroviral drug variables (ART table) 
Table 3 details the data on antiretroviral treatment that should be included in the ART table. 
As previously mentioned, preferably we will receive one line per drug, each with its 
prescription, start and stop date.   
Notes: 
All antiretroviral drugs to which a patient has been exposed (including PMTCT exposure of 
both pregnant women and infants peri- or postnatally) and PEP should be included with 
either the dates of starting and stopping the individual drugs, OR the number of doses OR 
the duration of treatment.  
 History of exposure to antiretroviral drugs prior to commencing care at the reporting 
facility should be reconstructed as far as possible and included in this table, making 
use of appropriate drug codes for unknown regimens and date/time codes for 
unknown start and stop dates or unknown durations.  
 
 
Table 3 – Variables to be included in ART table 
Name Format and definitions Description 
MERGE Numeric Number of merge 
PATIENT Free (numerical or alphanumerical) Unique, anonymous, patient identifier 
COHORT Text Text field identifying the cohort 
ART_ID ATC (for example NVP – see List 10) Type of antiretroviral drug 
ART_TXT Text ?UCT 
ART_SD_DMY Date(dd-mm-yyyy) Date of starting each antiretroviral 
drug (start date). 
Enter exact date in this field if known. 
 If unknown leave blank and enter 
month and year as far as possible in 
fields below. 
ART_SD_Y Numeric (e.g. 2003) 
8888 = Exact start date entered in 
appropriate field 
9999 = Unknown despite attempting 
ascertainment 
9995 = Not ascertained 
Year of starting drug 
ART_SD_M Numeric (e.g. 7) 
88 = Exact start date entered in 
appropriate field 
99 = Unknown despite attempting 




Name Format and definitions Description 
ascertainment 
95 = Not ascertained 
ART_RS Numeric with codes 
(See List 11) 
Reason for receiving ART 
ART_FORM Numeric with codes: 
1 = Tablet/capsule 
2 = Syrup/Suspension 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Type of formulation 
ART_COMB Numeric with codes: 
1 = Individual drug 
2 = Part of a fixed dose combination  
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Is drug part of a fixed dose 
combination? 
ART_ED_DMY Date(dd-mm-yyyy) Date of stopping each antiretroviral 
drug (end date) 
Enter exact date in this field if known. 
 If unknown leave blank and enter 
EITHER month and year as far as 
possible in fields below OR number of 
doses OR duration in weeks in the 
appropriate fields. 
Name Format and definitons Description 
ART_ED_Y Numeric (e.g. 2004) 
8888 = exact end date or number of 
doses or duration in weeks entered in 
appropriate fields 
9999 = Unknown despite attempting 
ascertainment 
9995 = Not ascertained 
Year of stopping drug 
ART_ED_M Numeric (e.g. 7) 
88 = exact end date or number of 
doses or duration in weeks entered in 
appropriate fields 
99 = Unknown despite attempting 
ascertainment 
95 = Not ascertained 
Month of stopping drug 
NO_DOSES Numeric (e.g. 1) Number of doses of drug e.g. 1 for 
single dose Nevirapine 
NO_WEEKS Numeric (e.g. 12) Number of weeks of receiving drug  
e.g. 12 for AZT from 28 weeks of 
pregnancy delivering at term 
ART_END_RS_TXT Text ?UCT 
ART_END_RS Numeric with codes 
(See List 12) 




Numeric Reason for stopping antiretroviral 
drug – revised code 
INFO_SOURCE Numeric with codes  
1 = Clinical records at this facility 
2 = Clinical records/letter from 
      another facility 
3 = Patient/caregiver report 
4 = Likely protocol in use 
90 = Other 
99 = Unknown 




Name Format and definitions Description 
COMMENTS Text ?UCT 
List 10: Anti-retroviral drugs :  (ART_ID) 
Code source: ATC classification: Anatomical Therapeutic Chemical 
Table name: LU :ART :ART_ID 
ATC codes Antiretroviral treatment 
J05A Drug unspecified (i.e. single drug, totally unknown) 
J05A-BEV Beviramat 
J05AE  PI unspecified  
J05AE01  Saquinavir (gel, not specified)  
J05AE01-SQH  Saquinavir hard gel (INVIRASE)  
J05AE01-SQS  Saquinavir soft gel (FORTOVASE)  
J05AE02  Indinavir (CRIXIVAN)  
J05AE03  Ritonavir (NORVIR) 
J05AE03-H  Ritonavir high dose (NORVIR)  
ATC codes Antiretroviral treatment 
J05AE03-L  Ritonavir low dose (NORVIR)  
J05AE04  Nelfinavir(VIRACEPT) 
J05AE05  Amprenavir (141W94) (AGENERASE)  
J05AE06  Lopinavir/Ritonavir (ABT-378/r, Kaletra)  
J05AE07  Fosamprenavir  
J05AE08 Atazanavir (Reyataz) 
J05AE09 Tipranavir (Aptivus) 
J05AE10 Darunavir 
J05AE-GW4  GW433908/VX-275 (Drug phase III) (PROGENERASE)  
J05AE-MOZ Mozenavir (DMP-450) 
J05AE-TMC  TMC 114 (Tibotec)  
J05AF  NRTI unspecified 
J05AF01 Zidovudine (AZT, RETROVIR)  
J05AF02  Didanosine (ddI) (VIDEX)  
J05AF03  Zalcitabine (ddC) (HIVID)  
J05AF04  Stavudine (d4T) (ZERIT)  
J05AF05  Lamivudine (3TC, EPIVIR)  
J05AF06  Abacavir (1592U89) (ZIAGEN)  
J05AF07 Tenofovir (TDF, VIREAD)  
J05AF08  Adefovir (PREVEON)  
J05AF09  Emtricitabine (FTC, EMTRIVA)  
J05AF10  Entecavir  
J05AF11 Telbivudine 
J05AF30-COV FDC5 (Stavudine/Lamivudine, d4T/3TC) 
J05AF-ALO Alovudine 
J05AF-AMD Amdoxovir (DADP) 
J05AF-FOZ  Fozivudinetidoxi 
J05AF-LDN Lodenosine (trialdrug)  
J05AF-RVT Reverset 
J05AG NNRTI unspecified  
J05AG01  Nevirapine (VIRAMUNE)  




J05AG02  Delavirdine (U-90152) (RESCRIPTOR)  
J05AG03  Efavirenz (DMP-266) (STOCRIN, SUSTIVA)  
J05AG-CPV Capravirine 
J05AG-DPC083 DPC 083 
J05AG-DPC961 DPC 961 
J05AG-EMV Emivirine (MKC442) 
J05AG-ETV Etravirine 
J05AG-LOV  Loviride  
J05AG-RPV Rilpivirine 
J05AG-TMC  TMC 125 (Tibotec)  
J05A-PBT  Participant in Blinded Trial  
J05AR ART regimen and drug unspecified (i.e. both number and names of 
drugs totally unknown) 
J05AR01 Combivir (Zidovudine/Lamivudine, AZT/3TC) 
J05AR02 Kivexa (Lamivudine/Abacavir) 
ATC codes Antiretroviral treatment 
J05AR03 Truvada (Tenofovir/Emtricabine, TDF/FTC) 
J05AR04 Trizivir (Zidovudine/Lamivudine/Abacavir) 
J05AR05 Douvir-N (Zidovudine/Lamivudine/Nevirapine) 
J05AR06 Atripla (Emtricitabine/Tenofovir/Efavirenz) 
J05A-TRM FDC1 (Stavudine/ Lamivudine/ Nevirapine, d4T/3TC/NVP) 
J05AX07  Enfurvirtide (FUZEON, T-20/Ro 29-9800)  
J05AX08 Raltegravir 
J05AX09 Maraviroc 
J05AX-EVG Elvitegravir (Gilead) 
J05AX-VIC Vicriviroc 
L01XX05  Hydroxyurea/Hydroxycarbamid (LITALIR)  
 
List 11: Codes for reason for receiving ART (ART_RS) 
Code source: IeDEA SA codes  
Table name: LU: ART: ART_RS 
Codes Reason 
10 MTCT – antenatal (mother) 
11 MTCT – peripartum (mother) 
12 MTCT – postpartum (mother) 
13 MTCT – timing unknown (mother) 
20 MTCT – peripartum (infant) 
21 MTCT – postpartum (infant) 
22 MTCT – timing unknown (infant) 
30 ARV as treatment 
 
40 PEP 
95 Not ascertained 







List 12: Reason for treatment discontinuation (ART_END_RS) 
Code source: HICDEP codes; new codes denoted by * 
Table name: LU :ART :ART_END_RS 
 
Note: Reasons for stopping treatment are grouped by similarity. The broad reason is 
indicated by the integer, while subcategories of that reason are denoted by figures to the 
right of the decimal point. Reasons should therefore be coded to the greatest level of detail 
that the data permits.  
For example, if a drug was stopped because of treatment failure determined by a declining 
CD4 count, the stop reason should be coded as 1.3; however if the reason for stopping is 
simply ―treatment failure‖ with the means of determining this not specified, the stop reason 




REVISEDC ART_END_RS AE CI FL OTHER 
1 1 Treatment failure (i.e. virological, immunological, 
and /or clinical failure) 
  1  
1.1 1.10 Virological failure   1  
1.2 1.20 Partial virological failure   1  
1.3 1.30 Immunological failure – CD4 drop   1  
1.4 1.40 Clinical progression   1  
2 2 Abnormal fat redistribution 1    
3 3 Concern of cardiovascular disease 1    
3.1 3.10 Dyslipidaemia 1    
3.2 3.20 Cardiovascular disease 1    
4 4 Hypersensitivity reaction 1    
5 5 Toxicity, predominantly from abdomen/G-I tract 1    
5.1 5.10 Toxicity – GI tract 1    
5.2 5.20 Toxicity – Liver 1    
5.3 5.30 Toxicity – Pancreas 1    
6 6 Toxicity, predominantly from nervous system 1    
6.1 6.10 Toxicity - peripheral neuropathy 1    
98 6.20 Toxicity - neuropsychiatric 1    
98 6.30 Toxicity - headache 1    
7 7 Toxicity, predominantly from kidneys 1    
8 8 Toxicity, predominantly from endocrine system 1    
8.1 8.10 Diabetes 1    
9 9 Haematological toxicity (anemia …etc.) 1    
10 10 Hyperlactataemie/lactic acidosis 1    
91 11.90 Toxicity, not mentioned above 1    
98 11.99 Toxicity - unspecified 1    
90.1 12 Comorbidity  1   
92.3 13 Drug interaction  1   
92.4 13.10 Drug interaction - commencing TB treatment  1   
92.5 13.20 Drug interaction ended - stopping TB treatment    1 
96 14 Pregnancy  1   
98 14.10 Pregnancy intended  1   
96.2 14.20 Pregnancy ended    1 
98 15 Social contra-indication  1   
98 16.90 Contra-indication - other  1   
98 16.99 Contra-indication unspecified  1   







REVISEDC ART_END_RS AE CI FL OTHER 
94.1 18.10 Non-compliance    1 
98 18.20 Defaulter    1 
98 19 Change in treatment not due to side-effects, 
failure, poor adherence or contra-indication 
   1 
92 19.10 Availability of more effective treatment (not 
specifically failure or side effect related) 
   1 
92.1 19.20 Simplified treatment available    1 
92.2 19.21 Treatment too complex    1 
98 19.30 Change in eligibility criteria (e.g. child old enough 
for tablets; refrigerator no longer available) 
   1 
98 19.40 Protocol change    1 
97 19.51 Study treatment    1 
98 19.52 Study treatment completed    1 
98 19.60 Drug not available    1 
93 19.70 Structured Treatment Interruption (STI)    1 
93.1 19.71 Structured Treatment Interruption (STI) – at high 
CD4 
   1 
94 19.80 Patient's wish/ decision, not specified above    1 
95 19.90 Physician‘s decision, not specified above (note 
overlap with standard code 
   1 
95.1 20 Contra-indication expired    1 
88 88 Death (note overlap with N/A in other lists)    1 
90 90 Side effects – any of the above but unspecified 1    
99.5 95 Not ascertained    1 
98 98 Other causes, not specified above    1 
99 99 Unknown despite attempting ascertainment    1 
*Second merge should only utilise this field. The old code has been given for lookup reference 
purposed for previously supplied data. 
2.4 Opportunistic events (OI table) 
Table 4 below details the data on opportunistic events or HIV associated conditions 
diagnosed during follow up that should be included in table OI. 
History of opportunistic events prior to commencing care at the reporting facility should be 
reconstructed as far as possible and included in this table, making use of appropriate 
date/time codes for unknown start and end dates. It is anticipated that the end date of OIs 





Table 4 – Variables to be included in OI table 
Name Format and definitions Description 
MERGE Numeric Number of merge 
PATIENT Free (numerical or alphanumerical) Unique, anonymous, patient identifier 
COHORT Text Text field identifying the cohort 
OI_ID Text (for example PCP - see List 3 – 
Disease codes – under PAT table) 
Type of opportunistic event 
OI_SD_DMY Date(dd-mm-yyyy) Date of start of each opportunistic event. 
Enter exact date in this field if known. 
 If unknown leave blank and enter month and 
year as far as possible in fields below. 
OI_SD_Y Numeric (e.g. 2001) 
8888 = Not applicable 
(Exact date entered in field above) 
9995 = Not ascertained 
9999 = Unknown despite attempting 
ascertainment 
Year of start of event 
OI_SD_M Numeric (e.g. 11) 
88 = Not applicable  
(Exact date entered in field above) 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Month of start of event 
OI_ED_DMY Date(dd-mm-yyyy) Date of end of each opportunistic event. 
Enter exact date in this field if known. 
 If unknown leave blank and enter month and 
year as far as possible in fields below 
If OI is ongoing (has not yet ended) leave 
blank and enter appropriate code in field below 
OI_ED_Y Numeric (e.g. 2001) 
8885 = Ongoing 
8888 = Not applicable 
(Exact date entered in field above) 
9995 = Not ascertained 
9999 = Unknown despite attempting 
ascertainment 
Year of end of event 
OI_ED_M Numeric (e.g. 11) 
85 = Ongoing 
88 = Not applicable  
(Exact date entered in field above) 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Month of end of event 





List 13: Diagnosis Method of Opportunistic Event (DIAG_METH) 
Code source: IeDEA SA codes 
Table name: LU :OI :DIAG_METH 
 
Codes Diagnosis Method 
10 clinical only 
11 clinical & radiology 
12 clinical and endoscopy 
20 microscopy for infectious agent 
21 culture of infectious agent 
30 blood antibody test 
31 site specimen (non-blood) antibody test 
40 tissue histology 
90 other 
95 Not ascertained 
99 Unknown despite attempting ascertainment 
2. 5 Follow-up clinic visits (VIS&VIS_HEUtables) 
Table 5 below details the information to be included in the VIS table. Please include all visits 
for each patient since the first visit at the reporting facility, and where possible visits at 
previous facilities. Weight, height and head circumference left blank will be assumed to have 
not been ascertained. 
Table 5.1 – Variables to be included in VIS table 
Name Format and definitions Description 
MERGE Numeric Number of merge 
PATIENT Free (numerical or alphanumerical) Unique, anonymous, patient identifier 
COHORT Text Text field identifying the cohort 
VISIT_DMY Date (for example dd/mm/yy) Date of visit patient 
VISIT_FAC Numeric with codes 
1 = Visit at this cohort‘s facility 
2 = Visit at another facility 
99 = Site of visit unknown 
Facility at which visit took place 
WEIGHT Numeric (e.g 3.20) Weight in kilos (kg) 
HEIGHT Numeric (e.g 75) Height in centimeters (cm) 
CTX Numeric with codes : 
1 = yes 
0 = No 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Cotrimoxazole status 
INH_STATUS_Y Numeric with codes : 
1 = Yes 
0 = No 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Isoniazid status 
FLU_STATUS_Y Numeric with codes : 
1 = Yes 





Name Format and definitions Description 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
HEADC Numeric (for example 75) Head circumference in centimeters 
(cm) 
SCHOOL_Y Numeric with codes 
0 = No school 
1 = At school 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Schooling for children >5 years.  




Table 5.2 – Variables to be included in VIS_HEU table 
Name Format and definitions Description 
PATIENT Free (numerical or alphanumerical) Patient identifier from VIS table 
VISIT_DMY Date (for example dd/mm/yy) Date of visit patient from VIS table 
CAREG Numeric with codes (see List 7) Primary caregiver at start of HAART 
(HAART_DMY) 
(paediatric patients only – enter 88 for adult 
patients) 
BRSTFD Numeric with codes 
10 = breastfeeding, exclusive 
11 = breastfeeding, exclusivity 
unknown  
12 = mixed feeding (breast- and 
formula feeding) 
13 = Breastfeeding, weaning started 
(solids introduced) 
20 = Formula feeding 
21 = Formula feeding, weaning 
started 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown, despite attempting 
ascertainment 
Infant feeding option at current visit 
 
This will be applicable from birth until infant on 
family foods 
 
(paediatric patients only - enter 88 for adult 
patients) 
BRSTFD_PROBLEM Numeric with codes: 
Any problems with breastfeeding? 
Masititis/cracked nipples etc 
0 = no problems with breastfeeding 
1 = problem with breastfeeding but 
cause unknown  
11 = mastitis 
12 = cracked nipples 
13 = perceived insufficient milk 
supply 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown, despite attempting 
ascertainment 
Problems preventing adequate breastfeeding 
at current visit  
(HEU patients only – enter 88 for adult patients 
and known HIV-infected children) 
SOLIDS_Y Numeric with codes 
0 = no, solids not introduced 
1 = yes, solids introduced 
88 = Not applicable 
Has the infant been introduced to solid foods 
yet at current visit (any type e.g. 
porridge/cereal/vegetables/fruit/yoghurt) 




Name Format and definitions Description 
95 = Not ascertained 
99 = Unknown, despite attempting 
ascertainment 
?type of solids (this assessed in 
Karl‘s data from visit 3) 
and known HIV-infected children) 
MUAC Numeric Mid-upper arm circumference in centimeters 
(cm)  
(HEU patients only – enter 88 for adult patients 
and known HIV-infected children) 
 
3 Variables to be included in additional tables 
3.1 Family and partner linkages (LINK table) 
Table 6 details the information on family members (partners, children and siblings) that 
should be included in the LINK table. 
All family members receiving HIV care should be listed. This includes those receiving care 
within the reporting cohort as well as those receiving care at other sites. 
The cohort-specific identifiers of family members receiving HIV care at the reporting site 
should be included.  
Table 6– Variables to be included in the table LINK 
Name Format and definitions Description 
MERGE Numeric Number of merge 
PATIENT Free (numerical or 
alphanumerical) 
Unique, anonymous, patient identifier 
COHORT Text Text field identifying the cohort 
LINK_REL Numeric with codes (See List 14) Relationship of family member to patient 
LINK_COHORT Text with codes (See List 15) Cohort within which family member is 
receiving HIV care 
LINK_ID Free (numerical or 
alphanumerical) 






List 14 - Codes for relationship of family member to patient (LINK_REL) 
Code source: IeDEA SA codes 








95  Not ascertained 
99 Unknown despite attempting ascertainment 
 
List 15 - Cohort where family member is receiving care (LINK_COHORT) 
Code source: To be created by transferring site 
Table name: LU :LINK :LINK_COHORT 
Codes Cohort 
Cohort ID Cohort description 
3.2 Pregnancy information (PREG table) 
Table 7 details information to be included in the PREG table. This table contains information 
on all pregnancies since the patient was known to be HIV-infected, including spontaneous 
abortions/ miscarriages and terminated pregnancies, and their outcomes.  
Table 7 – Variables to be included in PREGNANCY table 
Name Format and definitions Description 
MERGE Numeric Number of merge 
PATIENT_MOTHER Free (numerical or alphanumerical) Unique, anonymous, patient identifier 
PATIENT_CHILD Free (numerical or alphanumerical) Unique, anonymous, patient identifier 
COHORT Text Text field identifying the cohort 
PREG_DIAG_DMY Date (dd-mm-yyyy) Exact date when patient first presents 
as pregnant 
PREG_DUR_DIAG Numeric (e.g. 12) Estimated duration of pregnancy in 
weeks when patient first presents as 
pregnant 
PREG_END_DMY Date (dd-mm-yyyy) Exact date of delivery, spontaneous 
abortion or termination 
Enter exact date in this field if known. 
 If unknown leave blank and enter 
month and year as far as possible in 
fields below. 
PREG_END_Y Numeric (e.g. 2003) 
8888 = Not applicable 
(Exact date entered in field above) 
9995 = Not ascertained 
9999 = Unknown despite attempting 
ascertainment 
Year of delivery, spontaneous 




Name Format and definitions Description 
PREG_END_M Numeric (e.g. 9) 
88 = Not applicable 
(Exact date entered in field above) 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Month of delivery, spontaneous 
abortion or termination 
PREG_ED Numeric (e.g. 36) Estimated duration of entire 
pregnancy in weeks 
PREG_OUTCOME Numeric with codes  
1 = Live birth 
2 = Still birth 
3 = Termination of pregnancy 
4= Spontaneous abortion 
     (miscarriage) 
95 = Not ascertained 
99 = Unknown despite attempting 
        ascertainment 
Outcome of pregnancy 
 
If the pregnancy outcome is a live 
birth (1), please complete the infant 
table as well. 
PARITY Numeric Number of children 
GRAVIDA Numeric Number of pregnancies 
MIS_PREV Numeric with codes 
0= No 
1= Yes 
Whether there has been a previous 
miscarriage 
PREM_PREM Numeric with codes 
0=No 
1= Yes 
Has a previous pregnancy ended in a 
preterm delivery (prior 37 weeks) 
PLANNED_PREG Numeric with codes 
0= No 
1 = Yes 
Was this current pregnancy planned 
or not. 
 
3.3 Infant birth information (INFANT table) 
Table 8 details information to be included in the INFANT table. This table contains 
information, at birth,  on all children bornfrom a mothers  known to be HIV-infected. 
Table 8 – Variables to be included in INFANT table 
Name Format and definitions Description 
MERGE Numeric Number of merge 
PATIENT_MOTHER Free (numerical or alphanumerical) Unique, anonymous, patient 
identifier 
PATIENT_CHILD Free (numerical or alphanumerical) Unique, anonymous, patient 
identifier 
BIRTH_DMY DATE (dd-mm-yyyy) Date of birth  
Enter exact date in this field if 
known. 
 If unknown leave blank and enter 
month and year as far as possible in 
fields below. 
BIRTH_Y Numeric (for example 1960) 
9995 = Not ascertained 
9999 = Unknown despite attempting 
ascertainment 
Year of birth 
BIRTH_M Numeric (for example 8) 
95 = Not ascertained 




Name Format and definitions Description 
99 = Unknown despite attempting 
ascertainment 
COHORT Text Text field identifying the cohort 
WEIGHT Numeric (for example 75) Birth weight in kilos (kg) 
HEIGHT Numeric (for example 75) Birth height (length) in centimeters 
(cm) 
HEADC Numeric (for example 75) Birth head circumference in 
centimeters (cm) 
NEONATAL_DEATH Numeric with codes 
0 = No 
1 = Yes  
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Did delivered live infant die within 1 
month of birth? 
If stillbirth, spontaneous abortion or 
termination, enter 88 
BIRTH_DEFECT_Y Numeric with codes 
0 = No 
1 = Yes  
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 




Text Free text description of 
malformations 
DELIV_M Numeric with codes 
10 = Vaginal, spontaneous 
11 = Vaginal, forceps 
12 = Vaginal, vacuum 
20 = Caesarean section – 
primary/elective (before onset of 
labour and rupture of membranes) 
21 = Caesarean section – 
emergency 
22 = Caesarean section – type 
unknown 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Mode of delivery  
(paediatric patients only - enter 88 
for adult patients) 
APGAR1 Numeric (out of 10) Apgar at birth (out of 10) at 1min 
APGAR5 Numeric (out of 10) Apgar at birth (out  10) at 5min 
 
3.4 Parental Health (PAR_HEALTH table) 
Table 9 details variables to be included in the table PAR_HEALTH. This table contains 
information on parental health status.  
This table is linked to the visit table, so ideally there is an update on parental health status at 
every visit. Alternatively, this table should be filled in at least once, either for the first visit at 
your facility or the date of start of HAART.  
For patients over 16 years of age, no entries are required into this table (i.e. this table is not 




While information on parental health is very valuable, it is acknowledged that many sites do 
not collect this information. If only information at the child‘s first visit or at the start of HAART 
is collected, this should be included with the appropriate visit date. If no information on 
parental health is collected, this table can be omitted.   
Table 9: Variables to be included in the PAR_HEALTH table 
Name Format and definitions Description 
PATIENT Free (numerical or alphanumerical) Unique patient identifier for patient 
VIS_DMY 
Date (dd/mm/yy) 
Date of parental health 
evaluation  
(probably same as clinic visit 
date) 
MAT_DEATH Numeric with codes 
0 = No (Alive) 
1 = Yes (Dead) 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
Maternal status: Mother 
deceased? 
MAT_HIV Numeric with codes 
0 = Negative 
1 = Positive 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
Mother‘s HIV status if available 
MAT_TTT Numeric with codes 
0 = No treatment 
1 = CMX only 
2 = HAART only 
12 = CMX and HAART 
88 = Not applicable (mother HIV negative or 
deceased) 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
Mother‘s treatment if available 
PAT_DEATH Numeric with codes 
0 = No (Alive) 
1 = Yes (Dead) 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
Paternal status: Father 
deceased? 
PAT_HIV Numeric with codes 
0 = Negative 
1 = Positive 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
Father‘s HIV status if available 
PAT_TTT Numeric with codes 
0 = No treatment 
1 = CMX only 
2 = HAART only 
12 = CMX and HAART 




Name Format and definitions Description 
88 = Not applicable (father HIV negative or 
deceased) 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
 
 
3.5 Tuberculosis information (TB table) 
This table is for capturing details of the TB episodes during HIV follow-up.  Tests related to 
TB can be included in the LAB table.  Where possible this data can be derived from the 
electronic TB register. 
Table 10 – Variables to be included in the table TB 
Name Format and definitions Description 
MERGE Numeric Number of merge 
PATIENT Free (numerical or alphanumerical) Unique, anonymous, patient 
identifier 
COHORT Text Text field identifying the cohort 
REG_DMY Date (dd/mm/yy) Date registered with TB 
REGID Text (eg. 2272007) TB register number 
RAD Numeric with codes 
0 – Not done 
1 – Normal 
20 – Abnormal unspecified 
21 – Abnormal - not consistent with current 
TB 
22 – Abnormal - consistent with current TB 
unspecified 
23 – Abnormal – consistent with current TB 
– 
Cavity on right 
24 - Abnormal – consistent with current TB 
– 
Cavity on left 
25 - Abnormal – consistent with current TB 
– 
Bilateral cavities 
26 - Abnormal – consistent with current TB 
- 
No cavities 
99 = Unknown despite attempting 
ascertainment 
Radiography findings if done 
RESISTANT Numeric with codes 
0 – No 
1 – MDR 
2 – XDR 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Resistance data based on 
sensitivities 
Note: Exact results of 
sensitivities should be record in 
the LAB table.  Code as MDR if 
… to more than one drug and 
XDR if… 
Categories MDR and XDR 




Name Format and definitions Description 
resistance status during the 
episode.  
 
TB_START_DMY Date (dd/mm/yy) Date starting TB treatment 
TB_END_DMY Date (dd/mm/yy) Date ending TB treatment or date 
of outcome 
CAT Numeric with codes 
1 – Newly diagnosed for the first time 
2 – After relapse 
3 – After default 
4 – After failure 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
TB Category 
CLASS Numeric with codes 
1 - Pulmonary 
2 – Extra-pulmonary 
3 – Both pulmonary and extra-pulmonary 
4 - Primary 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Classification of episode 
SITE Numeric with codes 
1 – Bones/Joints (A18.0) 
2 – Lymph nodes (A16.3) 
3 – Meningitis (A17.0) 
4 – Miliary (A19.9) 
5 – Pleura (A16.5) 
9 – Other sites (A18.8) 
88 – Not applicable as pulmonary or 
primary only 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Site of disease if extra-pulmonary 
component diagnosed 
REGIMEN Numeric with codes 
1 – 2HRZE 4HR - Regimen 1 
2 –2HRZES 1HRZE 5HRE - Regimen 2 
3 – 2HRZ 4HR - Regimen 3 
4 –Other Regimen 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
TB treatment regimen 
REG_OTHER Text Text field for other regimen not 
included in codes for REGIMEN 
field above 
TB_OUTCOME Numeric with codes 
1 – Completed 
2 – Cured 
3 – Failed 
4 – Interrupted 
5 – Defaulted 
6 – Treatment ongoing 
7 - Died 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 





3.6 Trial/research study enrolment information (TRIAL table) 
Table 11 details the data that should be included in the TRIAL table.  This table is only for 
sites running trials or research studies. Any trial/research study (apart from cohort analysis 
of routine data) on which a patient has been enrolled should be entered together with the 
dates of entering and leaving each trial. Sites should send an additional coding table of the 
trials running at their site.  
 
Table 11 – Variables to be included in the table TRIAL 
Name Format and definitions Description 
PATIENT Free (numerical or alphanumerical) Unique patient identifier 
TRIAL_START_DMY Date (for example dd/mm/yy) Date of enrolment onto trial 
TRIAL_END_DMY Date (for example dd/mm/yy) 
Date of completion/ disenrolment 
Leave blank if patient is still enrolled on trial 
TRIAL_ID Free (numeric or text) codes (See List 
16) 
Name of trial on which patient is enrolled 
Each site to send their own List with coding and 
description of trial 
 
List 16: Example of codes for trial name (TRIAL_ID) 
Code source: Site to supply own codes 
Table name: LU :TRIAL :TRIAL_ID 
 
Codes  
(Text or Numeric) 
Trial name (text field) Short description of trial (Memo field) 
INH INH trial Trial of thrice weekly vs. daily INH prophylaxis in HIV-
infected children 
TB TB treatment duration trial Trial of 6 month vs. 9 month chemotherapy in HIV-
infected children 
 
4 Revised Death (Outcome) data 
This table contains information about death linkage data. 
 Table 12 – Variables to be included in the table OUTCOME_REV 
Name Format and definitions Description 
PATIENT 
Text  (numerical or 
alphanumerical) Unique patient identifier 
COHORT Text Name of the cohort  
REVISED OUTCOME Numeric with codes (See List 5) Revised outcome of death 
REVISED OUTCOME _DMY Date (for example dd/mm/yy) Date of revised outcome 
REVISION_DMY Date (for example dd/mm/yy) Date revision took place 




SOURCE Text Source of information update i.e. death registry 
5 Meta-data 
This table contains information about the data transfer itself. 
Table 13 – Variables to be included in the table META 
Name Format and definitions Description 
COHORT Text Name of the cohort  
ENROLS_DMY Date (for example dd/mm/yy) Date of start of enrolment 
ENROLE_DMY Date (for example dd/mm/yy) Date of end of enrolment 
FU_CLOSE_DMY Date (for example dd/mm/yy) Date of last possible follow-up 
ASC_DMY Date (for example dd/mm/yy) Date of last possible outcome ascertainment 
LTF_DEF Numeric For patients classified by the site as LTF, the number of days used to define LTF 
REPORTER Text Name of person responsible for data transfer 
TRANSFER_DMY Date (for example dd/mm/yy) Date extracted 
EMAIL Text Email address of site person responsible 
 
6 Facility-data 
This table contains information about the data facilities. 
Table 14 – Variables to be included in the table FACILITY_SET 
Name Format and definitions Description 
COHORT Text Text field identifying the cohort 
FACILITY Text Text field identifying particular clinic 
within cohort, if more than facility 
within the cohort 
PATIENT_PREFIX Free (numerical or alphanumerical) Prefix of the patient identifier. It 
includes the name of the cohort and 
facility and makes the patient 
identifier unique for the hole IeDEA-
database 
COHORT_old Text Text field identifying the cohort 
FACILITY_old Text Text field identifying particular clinic 
within cohort, if more than facility 
within the cohort 
PATIENT_PREFIX_old Free (numerical or alphanumerical) Prefix of the patient identifier. It 
includes the name of the cohort and 
facility and makes the patient 
identifier unique for the hole IeDEA-
database 
Name Format and definitions Description 
PATIENT_PREFIX_orig Free (numerical or alphanumerical) Prefix of the patient identifier. It 
includes the name of the cohort and 




identifier unique for the hole IeDEA-
database 
ECONOMY Numeric with codes 
1 = Urban 
2 = Rural 
Population served 
LEVEL_OF_CARE Numeric with codes (See List 17) Level of care 
ART_SD_Y Numeric (e.g. 2003) 
8888 = Exact start date entered in 
appropriate field 
9999 = Unknown despite attempting 
ascertainment 
9995 = Not ascertained 
Year of starting drug 
 
 
List 17: Example of codes for level of care (LEVEL_OF_CARE) 
 
Code source: IeDEA SA codes 
Table name: LU :FACILITY_SET: LEVEL_OF_CARE 
Codes Level of care 
1 District clinic 
2 District hospital 
3 Health centre 
4 Hospice 
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Appendix F: Manuscript supplementary material 
The tables below detail linear regression models including parity, maternal age and CD4 cell 
count. The number of dyads included is reduced compared to the models previously 
presented owing to incomplete data.  
In addition, the same linear regression models were conducted for normal weight infants 
only. The effects in normal weight infants remain constant when contrasted with all infants, 











unadjusted ß 95% CI p-value 
 




   
0 
  formula feeding 
 
0.194 -0.048; 0.436 0.116 
 
1.050 -0.510; 1.599 * 
formula feeding x age 
 
0.019 0.008; 0.030 0.001 
 
-0.053 -0.084; -0.022 0.001 
unknown feeding 
 
-0.063 -0.422; 0.295 0.730 
 
0.338 0.021; 0.655 0.037 
unknown feeding  x age 
 
0.002 -0.016; 0.020 0.840 
 
-0.033 -0.055; -0.011 0.004 
         birth weight ≥2500g 
 
0 
   
0 
  birth weight <2500g 
 
-2.303 -2.445; -2.160 * 
 
-2.293 -2.437; -2.150 * 
birth weight <2500g x age 0.055 0.043; 0.067 * 
 
0.055 0.0419; 0.067 * 
         age (weeks) 
 
0.034 0.028; 0.037 * 
 
0.025 0.012; 0.038 * 
         parity = 0 
 
0 
   
0 
  parity = 1 
 
0.222 0.062; 0.383 0.006 
 
0.213 0.081; 0.346 0.002 
parity = 1 x age 
 
-0.013 -0.024; -0.003 0.016 
 
-0.013 -0.024; -0.002 0.02 
parity = 2 
 
0.088 -0.061; 0.248 0.278 
 
0.193 0.050; 0.336 0.008 
parity = 2 x age 
 
-0.012 -0.023; -0.001 0.028 
 
-0.012 -0.024; -0.0002 0.046 
         CD4 ≥500 
 
0 
   
0 
  CD4 <200 
 
-0.317 -0.506; -0.128 0.001 
 
-0.107 -0.260; 0.046 0.169 
CD4 <200 x age 
 
0.009 -0.004; 0.022 0.174 
 
0.007 -0.006; 0.020 0.270 
200 < CD4 < 500 
 
-0.047 -0.190; 0.096 0.518 
 
0.042 -0.073; 0.157 0.475 
200 < CD4 < 500 x age 
 
0.006 -0.004; 0.016 0.234 
 
0.003 -0.006; 0.012 0.533 
         Male sex 
 
0 
   
0 
  Female sex  
 
-0.160 -0.282; -0.039 0.010 
 
0.021 -0.078; 0.119 0.679 
Female sex x age 
 
0.016 0.008; 0.024 * 
 
0.012 0.003; 0.020 0.006 
                  25-35 years¶ 
 
0 
   
0 
  young mother 
 
-0.026 -0.181; 0.130 0.746 
 
-0.005 -0.139; 0.128 0.936 
young mother x age 
 
-0.003 -0.014; 0.009 0.593 
 
-0.008 -0.019; 0.003 0.161 
older mother 
 
-0.233 -0.395; -0.072 0.005 
 
-0.089 -0.224; 0.045 0.193 
older mother x age 
 
-0.002 -0.013; 0.009 0.749 
 
-0.004 -0.015; 0.007 0.474 
         Any ARVs 
 
0 
   
0 
  no ARVs 
 
-0.356 -0.652; -0.60 0.018 
 
-0.045 -0.285; 0.194 0.711 
no ARVs x age 
 
-0.009 -0.031; 0.013 0.418 
 
-0.012 -0.033; 0.010 0.279 
ARVs missing information 
 
-0.182 -0.732; 0.368 0.517 
 
0.022 -0.417; 0.461 0.921 






Table 5 Longitudinal linear regression, weight-for-age z-scores among normal birth weight infants 
  
Model including parity ; n=1953 
 


































   
0 
   
0 
   
0 
  formula feeding 
 
0.067 -0.090; 0.223 0.403 
 
0.616 0.096; 1.136 0.020 
 
0.031 -0.081; 0.143 0.591 
 
0.083 -0.302; 0.468 0.672 
formula feeding x 
age 
 
0.024 0.016; 0.033 * 
 
-0.057 -0.086; -0.029 * 
 
0.023 0.017; 0.029 * 
 
-0.032 -0.051; -0.012 0.002 
unknown feeding 
 
-0.126 -0.395; 0.143 0.358 
 
0.108 -0.200; 0.416 0.491 
 
-0.065 -0.321; 0.191 0.618 
 
0.017 -0.269; 0.302 0.910 
unknown feeding  
x age 
 
0.003 -0.011; 0.018 0.646 
 
-0.038 -0.058; -0.018 * 
 
0.002 -0.012; 0.016 0.778 
 
-0.029 -0.046; -0.012 0.001 
                 age (weeks) 
 
0.022 0.019; 0.026 * 
 
0.014 0.007; 0.022 * 
 
0.025 0.023; 0.028 * 
 
0.011 0.007; 0.016 * 
                 Male sex 
 
0 
   
0 
   
0 
      Female sex 
 
0.040 -0.041; 0.121 0.336 
 
0.038 -0.043; 0.119 0.357 
 
0.043 -0.033; 0.120 0.267 
 
0.042 -0.034; 0.118 0.278 
Female sex x age 
 
0.015 0.008; 0.021 * 
 
0.015 0.009; 0.022 * 
 
0.011 0.006; 0.017 * 
 
0.012 0.007; 0.018 * 
                                  parity = 0 
 
0 
   
0 
   
ǂ 
   
ǂ 
  parity = 1 
 
0.160 0.054; 0.266 0.003 
 
0.149 0.044; 0.254 0.005 
 
ǂ 
   
ǂ 
  parity = 1 x age 
 
-0.005 -0.013; 0.004 0.261 
 
-0.001 -0.009; 0.007 0.772 
 
ǂ 
   
ǂ 
  parity = 2 
 
0.187 0.080; 0.294 0.001 
 
0.164 0.057; 0.271 0.003 
 
ǂ 
   
ǂ 
  
parity = 2 x age   -0.015 -0.023; -0.006 0.001   -0.008 
-0.017; 
0.0004 0.063   ǂ       ǂ     












unadjusted ß 95% CI p-value 
 




   
0 
  formula feeding 
 
0.014 -0.181; 0.208 0.889 
 
0.818 0.219; 1.417 0.007 
formula feeding x age 
 
0.028 0.017; 0.040 * 
 
-0.077 -0.113; -0.042 * 
unknown feeding 
 
-0.104 -0.414; 0.205 0.509 
 
0.273 -0.088; 0.633 0.138 
unknown feeding  x age 
 
0.005 -0.013; 0.024 0.561 
 
-0.053 -0.078; -0.038 * 
       birth weight ≥2500g 
 
ǂ 
   
ǂ 
  birth weight <2500g 
 
ǂ 
   
ǂ 
  birth weight <2500g x age ǂ 
   
ǂ 
           age (weeks) 
 
0.025 0.021; 0.030 * 
 
0.023 0.009; 0.037 * 
         parity = 0 
 
0 
   
0 
  parity = 1 
 
0.232 0.096; 0.368 0.001 
 
0.217 0.078; 0.357 0.002 
parity = 1 x age 
 
-0.017 -0.028; -0.006 0.003 
 
-0.014 -0.026; -0.003 0.016 
parity = 2 
 
0.201 0.064; 0.338 0.004 
 
0.193 0.040; 0.346 0.013 
parity = 2 x age 
 
-0.018 -0.029; -0.006 0.002 
 
-0.011 -0.024; 0.001 0.082 
         CD4 ≥500 
 
0 
   
0 
  CD4 <200 
 
-0.141 -0.306; 0.023 0.093 
 
-0.159 -0.323; 0.004 0.056 
CD4 <200 x age 
 
0.009 -0.005; 0.023 0.197 
 
0.012 -0.014; 0.026 0.079 
200 < CD4 < 500 
 
0.013 -0.107; 0.134 0.831 
 
0.008 -0.112; 0.128 0.897 
200 < CD4 < 500 x age 
 
0.004 -0.006; 0.014 0.399 
 
0.004 -0.006; 0.134 0.449 
         Male sex 
 
0 
   
0 
  Female sex (sex) 
 
0.010 -0.095; 0.114 0.856 
 
0.006 -0.098; 0.110 0.908 
sex x age 
 
0.013 0.004; 0.022 0.004 
 
0.014 0.005; 0.023 0.002 
                  25-35 years¶ 
 
0 
   
0 
  young mother 
 
-0.087 -0.218; 0.045 0.197 
 
-0.004 -0.144; 0.137 0.956 
young mother x age 
 
-0.002 -0.013; 0.009 0.759 
 
-0.010 -0.022; 0.002 0.108 
older mother 
 
-0.111 -0.253; 0.031 0.127 
 
-0.123 -0.270; 0.023 0.100 
older mother x age 
 
-0.005 -0.017; 0.006 0.365 
 
-0.004 -0.016; 0.008 0.503 
         Any ARVs 
 
0 
   
0 
  no ARVs 
 
0.024 -0.253; 0.300 0.866 
 
0.023 -0.252; 0.298 0.870 
no ARVs x age 
 
-0.032 -0.058; -0.006 0.014 
 
-0.030 -0.055; -0.003 0.028 
ARVs missing information 
 
0.270 -0.228; 0.767 0.288 
 
0.231 -0.262; 0.724 0.359 
ARVs missing information x age 
 
-0.033 -0.065; -0.0002 0.049   -0.024 -0.056; 0.008 0.143 
*p<0.0001 ǂNot included in the model 
